The expression of steroidogenic enzymes and their regulation in the pituitary gland. by Wong, Chiu. & Chinese University of Hong Kong Graduate School. Division of Chemical Pathology.
‘ - f x 
, c 
V v 
The Expression of Steroidogenic Enzpies and Their Regulation in the 
Pituitary Gland 
WONG Chiu 
A thesis Submitted in the Partial Fulfillment 
of the Requirements for the Degree of 
Master of Philosophy 
in 
Chemical Pathology 
• The Chinese University of Hong Kong 
July 2005 
The Chinese University of Hong Kong holds the copyright of this thesis. Any person(s) 
intending to use a part or whole of the materials in the thesis in a proposed publication must 
seek copyright release from the Dean of the Graduate School. 
统系‘書圃 
g ( 1 6 OCT » ) 1 
UNIVERSITY~~YMJL 
NgJgSJ-IBRARY SYSTEMy^ g/ 
^  
Abstract 
Steroidogenic enzymes expression and steroid production have been shown in a 
number of extra-adrenal and -gonadal tissues, most notably the brain, where 
neurosteroids are produced and function locally as neurotransmitters. Pituitary gland 
being one of the central organs that is responsible for regulating steroidogenesis in the 
adrenal cortex and gonads, has been less studied in as far as neurosteroids are 
concerned. An enigmatic finding of higher than peripheral blood Cortisol in the 
inferior petrosal sinus effluent of Gushing's disease patients undergoing corticotrophin 
releasing hormone (CRH) stimulation procedure for the lateralization of the 
microadenoma, prompted this research project. The aim of this project was to 
investigate whether the pituitary gland expresses the mRNAs for steroidogenic 
enzymes and their possible regulation. 
In this study, the expression of five steroidogenic enzyme mRNAs, namely 
side-chain cleavage enzyme (P450scc)，3|3-hydroxysteroid dehydrogenase (3p-HSD), 
21-hydroxylase (CYP21), 11 P-hydroxylase (CYPl lB l ) and 11 (3-hydroxysteroid 
dehydrogenase (lip-HSD-1) were studied in intact rat and mouse pituitary glands by 
RT-PCR. All steroidogenic enzyme genes were expressed in the rat pituitary, but at a 
lower level than in the adrenal gland. However, in the mouse pituitary, only SP-HSD 
and l lp-HSD-1 were expressed. Up-regulation of tropic hormones by surgical 
removal of adrenals and/or testis, or down-regulation by administration of 
dexamethasone and/or testosterone for three weeks did not affect the expression of 
steroidogenic enzymes niRNA in the rat pituitary. 
Studies with rat and mouse pituitary cell-lines, RC-4B/C and AtT-20 respectively, 
revealed a biphasic cAMP response to CRF. P450scc and 3P-HSD were expressed in 
RC-4B/C, while only 3p-HSD was expressed in AtT-20. The expression of 3P-HSD 
mRNA in AtT-20, but not P450scc and 3p-HSD mRNAs in RC-4B/C, was augmented 
i 
by CRH. 
These tentative results suggest that the pituitary gland expresses the mRNAs for 
steroidogenic enzymes, and therefore has the potential for steroidogenesis. For 
instance, the rat pituitary could possible convert cholesterol to corticosterone and 
metabolize it further to 11-dehydrocorticosterone. There is some evidence in the 
literature which supports the contention of steroidogenesis in the rat pituitary. But the 
occurrence of such event is species-specific. On one hand, the pituitary steroidogenic 
enzyme mRNA expression levels were not regulated by mechanisms that normally 
regulate steroidogenesis in conventional steroid hormone-producing tissues. On the 
other hand, the pituitary cell-lines, although not expressing the full range of 
steroidogenic enzyme mRNAs, showed some responsiveness to CRH. Further studies 
are needed to determine whether steroid hormones are actually secreted from the 
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The suggestion that the pituitary gland possesses the ability to produce steroid 
hormones was inferred by the detection of Cortisol in the effluent of the pituitary 
gland in five Gushing's disease patients undergoing inferior petrosal sinus (IPS) 
sampling to lateralize the microadenoma (Panesar et al., unpublished data). The levels 
of Cortisol in the pituitary effluents of these patients after corticotropin-releasing 
hormone (CRH) injection were higher than that in peripheral circulation by 8-45% at 
15 mill after the injection of releasing hormone. Although the IPS collects effluent 
from a substantial part of the brain and thus higher Cortisol could be emanating from 
any part of the brain. However its concurrence with the release of ACTH, is highly 
suggestive of the pituitary being the origin. Though ectopic steroidogenesis has 
become an increasingly familiar phenomenon in recent years, this finding challenges 
and complicates our present knowledge regarding steroidogenesis. Yet, the 
mechanisms by which steroid hormones are produced in the pituitary, whether in 
normal or adenomatous conditions, as well as its regulatory control remain a puzzle to 
be resolved. This part of the thesis summarizes the current information regarding the 
pituitary gland and steroidogenesis. 
a. Steroidogenesis 
Steroid hormones comprise of a cyclopentaphenanthrene skeleton derived from 
cholesterol. These include C-21 steroids, such as gluco- and mineralo-corticoids 
(corticosterone, Cortisol and aldosterone), C-19 steroids, mostly androgens 
(androstenedione, dehydroepiandrosterone and testosterone), and C-18 steroids such 
as estrogens (estrone, estradiol and estriol). 
1 
Introduction 
Steroidogenesis, the production of steroid hormones, is a multi-step process, 
from the uptake of cholesterol, transport of cholesterol within the cell, to the 
enzymatic conversion into active hormones (Figure 1.1). It mainly takes place in the 
adrenal cortex, testis or ovaries，and the placenta during pregnancy. The biological 
specificity of a steroid hormone produced is determined by the expression of a 
specific series of steroidogenic enzymes. 
i. Ectopic steroidogenesis 
Over the past two decades, an expanding body of evidence purports the 
production of steroid hormones in tissues other than the adrenal cortex, the gonads 
and the placenta. Among them, steroidogenesis in the central nervous system (CNS) 
has drawn most attention. The production of steroid hormones in the CNS, i.e. 
neurosteroids, and their physiological importance has been studied extensively 
[reviewed in (Mellon et al. 2001), (Mellon and Griffin 2002), (Mensah-Nyagan et al 
1999) and (Compagnone and Mellon 2000)]. The existence of neurosteroids was 
suggested following the discoveries of de novo synthesis of dehydroepiandrosterone 
(DHEA) (Corpechot et al. 1981) and pregnenolone (Corpechot et al. 1983) and their 
sulphates in the rat brain. The levels of these steroids were higher in the CNS than in 
the plasma before and after adrenalectomy and orchidectomy, which indicated in situ 
steroidogenesis in the CNS. Such steroidogenesis was enhanced by the addition of 
dibiityryl cAMP (Hu et al 1987) and stress - as shown by the administration of 
corticotropin-releasing factor (CRF) and adrenocorticotropin (ACTH) (Torres et al 
2001). In addition, steroidogenic enzymes mRNAs expression have been detected in 
most regions of the human brain (Yu et al. 2002) and rat brain (Stromstedt and 
Waterman 1995) without much difference between sexes (Kohchi et al. 1998). The 












































































































































































































































































































































































































































































adrenals and gonads, which makes the task of detecting them more difficult. The 
expression pattern of steroidogenic enzyme mRNAs in parts of the brain is different. 
Moreover, the presence of some steroidogenic enzymes mRNA does not equate de 
novo steroidogenesis, particularly considering that some key enzymes are absent, such 
as the side-chain cleavage enzyme. Therefore, the metabolism of steroid hormones in 
each brain region is different, in accordance with the series of steroidogenic enzymes 
expressed locally. 
The role of neurosteroids in the CNS is not yet fully defined, but it may be 
related to neuronal activity in stress, depression and memory. However, it is 
well-established that the mechanism of neurosteroid action in the CNS is variable. 
Neurosteroids mediate their actions through binding to classical neuronal receptors 
and to ion-gated neurotransmitter receptors, and by modulation of other 
neurotransmitter receptors. For example, progesterone derivatives were found to act 
as negative modulator of G A B A A channel and to inhibit GABA-ergic function; 
DHEA and DHEAS stimulate embryonic axonal and dendritic growth respectively 
(Mellon et al 2001). 
Apart from the CNS, steroidogenic enzyme mRNAs have also been detected in 
other tissues. The expression of CYPl lB l and CYP11B2 have been reported in 
failing human and mouse heart, but not in normal hearts (Young et al. 2001). The 
pathophysiological relevance of these expressions in heart disease is not clear 
(Gomez-Sanchez and Gomez-Sanchez 2001). Their expressions have also been 
reported in the normal rat heart. Corticosterone and aldosterone levels in the rat heart 
perfusate and homogenate are up-regulated by both ACTH and angiotensin II 
(Silvestre et al. 1998). Besides, it was demonstrated that all the enzymes required for 
glucocorticoid synthesis are expressed in the murine thymus (Lechner et al 2000), 




a. Steroidogenesis in the pituitary 
Studies on de novo steroidogenesis in the pituitary are scarce. Thus far only 
3P-HSD (Vidal et al. 2000) and 11 P-HSD type 1 and 2 (Moisan et al 1990) mRNA 
expressions have been detected in normal rat pituitary. The regulation of the 
bioactivity of 11 p-HSD type 1 in the pituitary by various adrenalcorticosteroids has 
been investigated (Idrus et al 1996). It was found to colocalize with 
mineralocorticoid receptor (MR), in the brain and pituitary, thus protecting the MR 
from binding with excessive glucocorticoid. The expression of 11 p-HSD also takes 
part in pathological condition. In pituitary ACTH-secreting adenoma, the predominant 
expression of type 2 11 p-HSD over its type 1 isozyme was shown (Korbonits et al. 
2001). Type 2 11 p-HSD converts Cortisol to the inert cortisone. This may reduce the 
amount of Cortisol for the negative feedback on pituitary production of ACTH. Other 
studies mainly focus on the ability of the pituitary to metabolize steroid hormones 
from exogenous sources. As early as 1975, 3a-hydroxysteroid dehydrogenase 
(3a-HSD) was characterized in the rat pituitary that converts dihydrotestosterone 
(DHT) to androstenediol (Thien et al 1975). With the presence of 3a-HSD, the 
intermediate lobe of rat pituitary is capable of converting progesterone to 
3a-hydroxy-5-pregnan-20-one (5aP3a) (Berman et al. 1998). In addition, the 
conversion of progesterone into a number of steroid derivatives has been 
demonstrated in the rat pituitary, most notably 3a-hydroxy-4-pregnen-20-one (3aHP), 
and its metabolism back into progesterone in a cyclic manner (Wiebe et al 1997). 
3aHP specifically inhibits the release of follicle-stimulating hormone (FSH) without 
an effect on luteinizing hormone (LH) in the pituitary. This indicates that FSH 
synthesis in the pituitary is regulated partly by an autocrine or paracrine factor. 
5 
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Besides, 5a-reductase (5a-R) was also characterized in the pituitary gland as it 
converts progesterone to 5a-dihydroprogesterone (Cheng and Karavolas 1975). The 
latter is more potent in exerting negative feedback on the 
hypothalamus-pituitary-adreiial (HPA) axis. Recently, aromatase P450 (P450aro) 
expression was detected in the rat pituitary by immimohistochemical methods, 
preferentially in male rats (Carretero et al 1999). P450arom converts 19-carbon 
androgens into 18-carbon estrogens. The expression of P450arom in male rat pituitary 
can be related to its response to sex steroids，such as estradiol. 
in. Proteins and enzymes involved in steroidogenesis and their distribution in brain 
and other sites 
Steroidogenic acute regulatory protein (StAR) 
In general, steroidogenesis commences in response to the interaction of a tropic 
hormone with its specific receptor in a steroidogenic tissue, and the de novo synthesis 
of StAR protein. The latter is a rate-limiting step. StAR transports the freed 
cholesterol from the cytosol into the inner mitochondrial matrix through its membrane 
(Stocco and Clark 1996). Its mRNA and protein are expressed throughout the whole 
human and mouse brain (King et al 2002). 
Side-chain cleavage enzyme (P450scc) 
Synthesis of steroid hormones begins in the mitochondrial matrix, where 
cholesterol is hydroxylated at C20 and C22 followed by scission of the C20-C22 bond. 
These three reactions are catalyzed by the side-chain cleavage enzyme complex 
(P450scc), which produces pregnenolone and isocaproic acid. The tissue-specific 
expression and hormonal regulation of this enzyme are mediated by the binding of 
steroidogenic factor-1 (SF-1) onto the promoter region of its gene (Hu et al. 2004). 
6 
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P450scc mRNA is expressed in the rat fetal hippocampus (MacKenzie et al 2002), 
cerebrum, diencephalon, cerebellum, mesencephalon, (Kohchi et al. 1998)， spinal 
cord (Sanne and Krueger 1995), human heart (Kayes-Wandover and White 2000) and 
different parts of the human brain, such as caudate nucleus, corpus callosum, spinal 
cord, thalamus, hippocampus, cerebellum and amygdala (Yu et al. 2002). Its protein 
was detected immunohistochemically in rat cerebral cortex (Le Goascogne et al. 
1987). The mRNA and protein were also detected in rat kidney (Dalla Valle et al. 
2004). 
3p-hydroxysteroid dehydrogenase/isomerase (3p-HSD) 
3(3-HSD catalyses the P-oxidation of the hydroxyl group at C3 position，and A4 
to A5 isomerisation of pregnenolone to produce progesterone in the smooth 
endoplasmic reticulum (ER). The expression of the enzyme in the adrenal cortex is 
enhanced by ACTH through the cyclic adenosine monophosphate (cAMP) pathway 
(Naville et al. 1991). 3p-HSD is involved in the development of neonatal brain as its 
mRNA level in neonatal rat brain decreases progressively after the day of birth. 
(Ibanez et al 2003). Its mRNA is expressed in the whole brain of neonatal rat (Ibanez 
et al. 2003), cerebrum, cerebellum (Kohchi et al 1998), hypothalamus (Nishida et al 
2005), spinal cord (Sanne and Krueger 1995) (Coirini et al. 2002) and cochlea (Lecain 
et al 2003) of adult rat; In human, the mRNA expression is also detected in the heart 
(Kayes-Wandover and White 2000) and parts of the brain, such as caudate nucleus, 
corpus callosum，spinal cord, thalamus, hippocampus, cerebellum and amygdala (Yu 
et al. 2002). In addition, immunohistochemistry showed the presence of 3(3-HSD 




17a-hydroxylase possesses two catalytic properties: hydroxylation at C-17 
position and the scission of the C17-C20 bond. Substrates such as pregnenolone and 
progesterone are acted upon by 17a-hydroxylase to yield 17-hydroxypregnolone and 
17-hydroxyprogesterone respectively. After the cleavage of the C17-C22 bond, the 
latter two 17-hydroxysteroids are converted to C19 androgens, viz DHEA and 
androstenedione respectively. In rodent, CYP17 is not expressed in the adrenal gland, 
but its protein was found in gonads and liver by immunoblotting, where 19-C steroids, 
including androgens, are produced (Katagiri et al. 1998). CYP17 mRNA is also 
expressed in rat mesencephalon (Kohchi et al 1998) and cochlea (Lecain et al. 2003), 
and some regions of the human brain, such as caudate nucleus, corpus callosum, 
spinal cord, thalamus, hippocampus, cerebellum and amygdala (Yu et al. 2002). 
21-hydroxylase (CYP21) 
21 -hydroxylase is also located in smooth ER in the cytoplasm. It catalyzes the 
21 -hydroxylation of progesterone to deoxycorticosterone and 17-hydroxyprogesterone 
to deoxycortisol. CYP21 mRNA expression is detected in rat astrocytes (Lovelace et 
al 2003), and human hippocampus affected by epilepsy (Beyenburg et al. 2001). 
However, 21-hydroxylation in the rat brain is carried out by the cytochrome P450 2D 
(CYP2D) enzyme instead of 21-hydroxylase (Kishimoto et al. 2004). 
11 P-hydroxylase/ aldosterone synthase (CYPllBl /CYPl 1B2) 
These two enzymes are encoded by two highly homologous genes, C Y P l l B l 
and CYP11B2, respectively. Their nucleotide sequences and the amino acid sequences 
are homologous by 88 and 83%, respectively (Zhou et al 1994). Effort was made to 
enhance the specificity to differentiate the two genes using RT-PCR (Oaks and Raff 
8 
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1995). C Y P l l B l is expressed in the zona fasciculata and reticularis regions (ZFR) of 
the adrenal cortex, where 11 p-hydroxylase (P450cllp) is responsible for the 
11 P-hydroxylation of deoxycortisol to Cortisol, or deoxycorticosterone to 
corticosterone in rodents. CYP11B2 is expressed in the zona gomerulosa (ZG), where 
aldosterone synthase (P450aldo) sequentially performs 11 p-hydroxylation, 
18-hydroxylation and 18-oxidation of deoxycorticosterone to corticosterone, 
18-hydroxycoiticosterone and finally aldosterone (Domalik et al 1991). C Y P l l B l 
mRNA is expressed in rat fetal hippocampus (MacKenzie et al. 2002), cerebrum 
(Erdmann et al. 1997), Leydig cell (Wang et al. 2002), human heart (Kayes-Wandover 
and White 2000) and human brain parts, such as caudate nucleus, corpus callosum, 
spinal cord, thalamus and amygdala (Yu et al. 2002). The presence of its protein was 
confirmed by immunostaining in rat cerebellum (MacKenzie et al 2000) and 
myelinated fibres (Ozaki et al 1991), CYP11B2 mRNA, is similar to that of 
C Y P l l B l and expressed in rat fetal hippocampus (MacKenzie et al 2002), adult rat 
hypothalamus, hippocampus, amygdala, cerebrum, cerebellum (Gomez-Sanchez et al 
1997) and cochlea (Lecain et al 2003); and in human fetal heart (Kayes-Wandover 
and White 2000) and human brain parts, such as caudate nucleus, corpus callosum, 
spinal cord and thalamus (Yu et al 2002). The presence of its protein was shown by 
immunostaining in the rat cerebellum (MacKenzie et al. 2000). Despite the highly 
identical coding region for these two genes, their promoter regions are strikingly 
different, with only 48% homogeneity (Kawamoto et al 1992), suggesting the two 
enzymes, which respectively synthesize Cortisol and aldosterone (that regulate distinct 
functions) are regulated differentially. CYPl lB l expression in the ZFR region is 
mainly enhanced by ACTH (Rainey 1999) and suppressed by glucocorticoids (Malee 
and Mellon 1991); while the expression of CYP11B2 in the ZG and the CNS is 
regulated by dietary sodium and angiotensin II (Ye et al. 2003). 
9 
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Recent study found another functional member of the CYPl lB gene family, 
designated CYP11B3, whose mRNA is expressed in the adrenal and brain (cerebral 
cortex, cerebellum, hippocampus, hypothalamus, midbrain) of neonatal rat (Zhou et al. 
1995). The protein of this gene has not been detected thus far, but when its DNA was 
transfected into COS-7 cells, it carries out 18-hydroxyIation of corticosterone to form 
18-hydroxydeoxycorticosterone (Kawamoto et al 1992). 
11 P-hydroxysteroid dehydrogenase (11P-HSD) 
l ip-HSD is important in inactivating corticosteroids. There are two isoforms of 
11 P-HSD. Type 1 isoform has dual reversible function, which can oxidize 
cortisol/corticosterone to cortisone/dehyodrocorticosterone, respectively, and also 
reduce the latter to former. Type 2 isoform only catalyzes the oxidation reaction 
(Holmes et al 2003). Both type 1 and 2 11 P-HSD are important in amplifying 
glucocorticoid feedback on the HPA axis and regulating neuronal exposure to 
glucocorticoid action under both basal and stress conditions. 11 P-HSD type 1 
deficient mice showed elevated basal level of corticosterone and ACTH, and an 
exaggerated response to stress. These mice were also less sensitive to feedback 
suppression by exogenous Cortisol (Harris et al. 2001). l lp-HSD type 2 is usually 
expressed in mineralocorticoid target tissues to inactivate and hence prevent 
glucocorticoids from activating mineralocorticoid receptors (MR) (White 2003). 
11 P-HSD activity has been detected in the pituitary, and it colocalizes with MR. It 
may play a role in reducing the amount of the cortisol/corticosterone so as to enhance 
the sensitivity of the pituitary to slight fluctuation of corticosteroids in the circulation 
(Jellinck et al 1993). 11 P-HSD type 2 mRNA is expressed in ectopic ACTH-secreting 
cells in small cell lung cancer (Parks et al. 1998), as it inactivates glucocorticoids, 
removes the negative feedback on ACTH and leads to its uncontrolled synthesis. 
10 
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/v. Regulation of adrenal steroidogenesis 
Stimulation by ACTH 
Classical regulation of adrenal steroidogenesis at the hypothalamic and pituitary 
level is initiated by CRF secreted from the median eminence of hypothalamus, 
transported to the corticotrophs of the anterior pituitary, and triggers the synthesis and 
release of ACTH, which acts on the adrenal cortex. At the adrenal cortex, the action of 
ACTH is complex. On one hand, it stimulates the cAMP pathway, which leads to the 
activation of a range of enzymes, including the cholesterol esterase and the StAR 
protein in the short run, and the side-chain cleavage enzyme and other steroidogenic 
enzymes in the long run，resulting in the synthesis of pregnenolone in the 
mitochondria. On the other hand, ACTH modulates cGMP content, thus inactivates 
phosphodiesterase in an effort to increase cAMP concentration. Moreover, ACTH 
activates chloride ion channel through a Ras-dependent pathway. It also activates the 
rapid distribution of microfilament to the plasma membrane, which is essential for the 
translocation of G-protein to the membrane (Gallo-Payet et al 1999). 
Cyclic AMP-dependent and cAMP-independent regulation 
The sub-cellular signaling pathway leading to steroidogenesis is not only 
mediated through a cAMP-induced protein kinase pathway. There are other 
substances stimulating steroidogenesis not through the cAMP pathway, and examples 
include interleukins, a steroidogenic inducing protein (SIP) from follicular fluid, and 
calmidazolium. (Cooke 1999). Even for the action of cAMP on steroidogenesis, it is 
not only mediated through protein kinase, but is also coordinated by calcium ion, 




Local HPA in adrenal gland 
Interestingly, there is evidence for the presence of an intra-adrenal regulatory 
system of steroid hormone secretion. CRF can directly stimulate the secretion of 
corticosterone in the rat adrenal gland (Andreis et al. 1991). Immimoreactivities of 
CRF and expression of CRF receptor (CRFR) were detected in the adrenal medulla, 
which stimulates local production of ACTH in the adrenal medulla (Ehrhart-Bornstein 
et al. 1998; Vrezas et al. 2003). The adrenal production of CRF and ACTH is also 
under the suppression of Cortisol. This would complete a local "HPA axis" inside the 
adrenal gland. In CRFR type 1 deficient mice, administration of ACTH failed to 
stimulate corticosterone secretion from adrenal cortex despite a rise of ACTH receptor 
expression (Muller et al 2001). This suggests the participation of CRFRl in the 
ACTH-stimulated secretion of corticosterone in the adrenal cortex. 
Cross talk of HPA and HPG axes 
Apart from regulating its own secretion, the HPA axis is also interacting with the 
hypothalamic-pituitary-gonadal (HPG) axis (Viau 2002). Components of the two axes 
tend to be suppressive to each other. It was found that ACTH can stimulate the 
production of testosterone in the fetal and neonatal mouse testis (O'Shaughnessy et al. 
2003). Also, adrenal androgen production as response to ACTH can be up-regulated 
by testosterone (Polderman et al. 1994). Dehydroepiandrosterone (DHEA), an adrenal 
androgen, however, suppresses the systhesis of Cortisol in the adrenal cortex. DHEA 
inhibits the expression of StAR protein and reduces corticosterone release stimulated 
by ACTH, 8-Br-cAMP and 25-OH cholesterol (Chang et al 2003). By the same token, 
testicular steroidogenesis is directly inhibited by Cortisol which suppresses the 
expression of testicular CYP17 (Feiiske 1997). 
12 
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b. Regulation of Pituitary ACTH Secretion 
The pituitary gland is one of the central organs that regulates endocrine 
secretions, producing tropic hormones such as ACTH, FSH, and LH, which are vital 
for steroidogenesis. The secretion of these tropic hormones in turn is regulated by 
hypothalamic hormones, paracrine factors and negative feedback from target gland 
hormones. 
i. Hypothalamic regulation 
The secretion of the anterior pituitary tropic hormones is under the regulatory 
control of the hypothalamic and peripheral hormones. Although the anterior pituitary 
secretes six major hormones, the present literature review will only focus on the 
regulation of tropic hormones involved in steroidogenesis and in particular, the 
hypothalamic-pituitary-adrenal axis (HPA). Neurohormones, such as CRF, are 
synthesized in paraventricular neurons (PVN) of the hypothalamus, released from the 
median eminence and transported through the hypophyseal portal vessel system to 
access the anterior pituitary and exert stimulatory action. CRF binds to the G-protein 
linked receptor on cell surface of corticotrophs. The binding of the CRF receptor 
causes the activation of Gs protein, which in turn stimulates adenylate cyclase, to 
generate cAMP intracellularly (Giguere et al 1982) (Labrie et al. 1982). Cyclic AMP 
binds to protein kinase A (PKA) to induce a signal transduction cascade that leads to 
the transcription of POMC gene, hence synthesis of ACTH (Howell and Montague 
1971). The action of CRF also involves an elevation of intracellular Ca^ "^  ion and the 
depletion of CI" ion (Cooke et al. 1999). The action of CRF on corticotroph is 
potentiated by arginine vasopressin (AVP) (Giguere and Labrie 1982). CRF also 
down-regulates the expression of glucocorticoid receptor (GR) and MR in the 
hippocampus, and MR in the anterior pituitary (Hugin-Flores et al 2003)，both are 
13 
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sites of negative feedback by corticosteroid on ACTH synthesis, which attenuates the 
inhibitory action of corticosteroids. 
ii. Paracrine regulation 
The existence of paracrine interactions amongst corticotrophs within the anterior 
pituitary that self-regulate their secretion has been proposed (Schwartz et al. 1998). It 
has been shown that corticotrophs consist of two subpopulations, where one 
suppresses the proopiomelanocortin (POMC) transcription and ACTH secretion by the 
other through an inhibitory factor. The suppressed subpopulation, in contrast, 
stimulates POMC transcription and ACTH secretion of all corticotrophs with a 
stimulatory factor. Leukemia inhibitory factor (LIF), which is normally synthesized 
and secreted by the anterior pituitary, was identified as the stimulator of ACTH 
secretion (Schwartz et al 1999). In fact, a number of cytokines, such as LIF, IL-1, 
IL-6 and TNF-a are expressed in the pituitary and regulate the HPA axis (Chesnokova 
and Melmed 2002). They activate gene transcription by the putative nuclear factor KB 
( N F - K B ) pathway. During inflammatory stress, N F - K B attenuates the negative 
feedback by glucocorticoid on corticotrophs by preventing the transactivation of 
glucocorticoid-response gene, mediated via GR. Moreover, it promotes the expression 
of the inactive beta isoform of GR. These actions render the HPA axis unresponsive to 
the negative feedback inhibition by glucocorticoids, thus protect against excessive 
cytokine release since glucocorticoids are potent anti-inflammatory agents (Melmed 
2001). On the other hand, IL-6 was found to directly stimulate glucocorticoid release 
from the adrenal cortex in human, (Bornstein et al 2004) possibly with a similar role 
to auto-regulate inflammatory response. 
CRF mRNA is expressed in rat corticotrophs (Giraldi and Cavagnini 1998), and 
CRF up-regulates the ACTH secretion by corticotrophs in a paracrine and autocrine 
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fashion. Moreover, mRNA expression of ACTH receptor was detected in normal 
pituitary, but not in adenomatous counterparts (Morris et al. 2003), which implies 
paracrine negative feedback regulation of ACTH secretion exists, and is depressed in 
pathological conditions. 
Hi. Feedback regulation 
Anterior pituitary hormone secretion is also subject to negative feedback from 
peripheral tissues. Corticosteroids down-regulate the production of CRF and ACTH in 
the hypothalamus and anterior pituitary respectively by binding to type 2 
glucocorticoid receptors (Clark and Kemppainen 1994). It is interesting to note that 
both CRF and glucocorticoids can down-regulate the expression of CRF receptor in 
the anterior pituitary (Pozzoli et al. 1996; Iredale and Duman 1997) so as to reduce 
the stimulus of CRF on ACTH synthesis in the pituitary. Corticosterone can inhibit 
proliferation and induce morphological shrinkage of prolactin-secreting cells in the 
pituitary (Carretero et al 1997) indicating cross-reactivity between the different 
anterior pituitary cell-types. In contrast, other studies have reported that 
dexamethasone can directly up-regulate the activity of P450scc (Picard-Hagen et al. 
1995) expression of StAR and 3(3-HSD mRNA, and the secretion of Cortisol in the 
adrenal gland (Feltus et al. 2002), indicating that glucocorticoid suppresses pituitary 
secretion on the one hand, but facilitates adrenal steroidogenic activities on the other 
hand. 
c. Aim of study 
This study was prompted by the surreptitious rise of Cortisol levels in the blood 
effusing from the pituitary gland before the systemic circulation in five Cushing's 
disease patients undergoing IPSS following CRF stimulation test (Panesar et al., 
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unpublished data). It should be noted that the pituitary is but one of the possible 
source of the high Cortisol in the IPS. The IPS also receives venous blood from a 
variety of organs, including the internal auditory veins, and veins from the medulla 
oblongata, pons, and the cerebellum. In spite of that, the pituitary remains a probable 
source of the Cortisol since Cortisol production in the brain in large amount has not 
been reported. On the other hand, there is tentative evidence suggesting that 
non-tumourous pituitary is also capable of steroidogenesis. Firstly, several studies 
have shown the expression of some key steroidogenic enzymes in the pituitary, such 
as 3P-HSD and 11(3-HSD, and the bioactivities of others, such as 3a-HSD and 
5a-reductase. The latter probably reflects the ability to metabolize steroid hormones 
locally and to modulate the function of the pituitary. Secondly, ACTH receptor is 
expressed in the pituitary, which may be responsible for the regulation of ACTH via 
the ultra-short loop negative feedback mechanism, but the possibility of the latter 
operating via locally synthesized steroids cannot be excluded. Moreover, since 
cytokines stimulate steroidogenesis in the adrenal cortex, and they are also expressed 
in the pituitary and stimulate ACTH secretion, the question arises as to whether they 
are involved in modulating pituitary endogenous steroid hormones production? 
Whether the pituitary expresses the complete series of steroidogenic enzymes, hence 
possesses the ability for de novo steroidogenesis remains a question. If it does, the 
type(s) of steroid hormone(s) produced and the regulatory mechanism are the major 
issues surrounding this novel phenomenon most required to be further investigated 
and addressed. 
Our study is divided into two parts, i.e. in vivo and in vitro experiments. In the in 
vivo experiment, the expression of steroidogenic enzymes mRNAs in non-tumourous 
rat pituitary would be detected by reverse transcriptase polymerase chain reaction 
(RT-PCR). The regulation of such expression would be studied either with the 
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injection of exogenous steroid hormones, i.e. dexamethasone and testosterone, which 
suppress pituitary ACTH and LH secretion respectively; or with the removal of 
steroidogenic organs, i.e. adrenal and testis by surgical mean which would augment 
the pituitary secretion. As for the in vitro experiments, two pituitary tumour cell-lines 
from rat and mouse would be used. The expression of steroidogenic enzymes mRNAs 
would be detected by RT-PCR. The cells would be treated with reagents that either 
regulate pituitary secretion or steroidogenesis, i.e. CRF. To determine if regulation of 
steroidogenic enzyme mRNA expression in these cells is mediated through the 
classical cAMP-dependent pathway, cAMP level would be measured using 
radioimmunoassay (RIA). 
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2. Materials and Methods 
a. Materials 
Animal model 
Male Sprague-Dawley rats were obtained from the Laboratory Animal Services 
Center (LASEC) of The Chinese University of Hong Kong. Rat chow was obtained 
from LabDiet (Brentwood, MO, USA). Rat pituitary cell-line RC-4B/C (Cat. No. 
CRL-1903) and mouse corticotroph cell-lines AtT-20 (Cat. No. CCL-89) were 
obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). 
Ethical approval of the animal use and experimental procedures were obtained from 
the Animal Ethical Committee of the University. 
Reagents 
RNeasy Mini total RNA isolation kit and QIAquick gel extraction kit were 
obtained from Qiagen Inc. (Vanlencia, CA, USA). Access RT-PCR system was 
obtained from Promega (Madison, WI, USA). BigDye Terminator v l . l cycle 
sequencing kit was obtained from Applied Biosystems (Foster City, CA, USA). 
Dexamethasone was obtained from Amersham (Cleverland, OH, USA). HEPES, 
bovine serum albumin (BSA), testosterone, forskolin, ethyldiaminetetraacetic acid 
(EDTA), Trizma Base (reagent grade) and corticotropin-releasing factor (CRF) 
(human, rat) were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Agarose 
was obtained from Invitrogen (Carlsbad, CA, USA). Restriction enzymes were 
obtained from New England Biolabs Inc. (Beverly, MA, USA). 
Cell culture reagents and plastic wares 
Dulbecco's modified Eagle's medium (DMEM), Ham's F12K, alpha minimum 
essential medium (a-MEM), dialyzed fetal bovine serum (FBS)，newborn calf serum 
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(NCS), horse serum, epithelial growth factor (EGF), L-glutamine, 
antibiotic-antimycotic (1,000 U/ml penicillin G, 1,000 |ig/ml streptomycin and 250 
ng/ml amphotericin B) and trypsin-EDTA (0.5% trypsin; 5.3 mM EDTA.4Na) (lOX) 
were obtained from GIBCO Corp. (Grand Island, NY, USA). Plastic culture wares 
were obtained either from Asahi Techno Glass (Tokyo, Japan), Corning Glass Works 
(Corning, NY, USA) or from BD Biosciences - Discovery Labware (Bedford, MA, 
USA). 
Solutions 
HEPES-phosphate Buffered Ringer (HPBR) solution was prepared with 135 mM 
NaCl, 5 mM KCl, 1 mM CaCh, 1 mM MgCb, 0.83 mM Na2HP04, 3.33 niM 
NaH2P04, 5 mM HEPES, 10 mM Glucose and 0.5% BSA. The salts were either 
obtained from Sigma, Merck (Darmstadt, Germany) or BDH Laboratory Supplies 
(Poole, UK). Hank's balanced salt solution (HBSS) with and without calcium and 
magnesium were obtained from Sigma. � 
Radioimmimoassav (RIA) reagents for cAMP 
Cyclic AMP assay buffer was prepared by dissolving 50 mM Tris-HCl and 4 mM 
EDTA in water, and adjusted to pH 7.5. Charcoal absorbent was prepared by 
dissolving 0.52% (w/v) activated charcoal, 0.052% dextran and BSA 0.4% in water. 
[8-^H] cAMP tracer (250 mCi) was obtained from DuPont (Boston, MA, USA). 
Scintillation cocktail was obtained from Beckman Coulter, Inc. (Fullerton, CA, USA). 
cAMP binding protein was prepared by an in-hoiise method (Farndale et al. 1992). 
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Oligonucleotide primers for RT-PCR 
Oligonucleotide primers for the reverse transcription-polymerase chain reaction 
(RT-PCR) amplification of messenger RNAs (mRNA) for steroidogenic enzymes, 
pituitary tropic hormones and internal controls were obtained from Operon 
Biotechnologies GmbH (Cologne, Germany). They were either adopted from 
literature or designed to span introns so as to prevent interference from genomic DNA. 
The primer sequences of rat mRNA are shown in Table 2.1 and those for mouse are 
shown ill Table 2.2. 
b. In vivo experiments 
Tissue collection 
The animals were sacrificed by cervical dislocation. The tissues, including 
adrenal glands, pituitary glands, liver, cerebral cortex and cerebellum were excised 
and frozen in liquid nitrogen immediately and stored in -70 until further use. 
mRNA extraction 
The tissues were first minced briefly with scissors while immersed in lysis buffer. 
They were then homogenized with a Polytron homogenizer (Kinematica AG, Lucerne, 
Switzerland) and passed through 21-G syringes at least 5 times. RNA extraction was 
then performed using RNeasy Mini total RNA isolation kit (Qiagen) following the 
manufacturer's instruction. Concentration of extracted mRNA was determined by 
measuring the optical density at 260 |_im in 1 cm cuvette (Eppendorf AG, Hamburg, 
Germany) in a bioplatemeter (Eppendorf AG) at 25-fold dilution. The mRNA was 




















































































































































































































































































































































































































































































































































































































































































































































Materials and Methods 
RT-PCR analysis 
Messenger RNA expression of steroidogenic enzymes was determined by 
RT-PCR with Access RT-PCR system (Promega). Briefly, a RT-PCR reaction mixture 
contained 2 i^l 5x AMV-T^Z reaction buffer, 1 mM magnesium sulphate, 0.2 mM dNTP, 
0.1 U/[i\ AMV reverse transcriptase and 0.1 U/|il Tfl DNA polymerase along with 0.1 
fj-g total RNA and 10 pmol of each of the forward and the reverse primers, in a final 
reaction volume of 10 )il made up with water. RT-PCRs were performed in a PTC-200 
thermal cycler (MJ Research, Reno, NV, USA), following manufacturer's (Promega) 
recommendations with slight modifications regarding PGR cycles and annealing 
temperatures, individualized for each gene and primer pair. Generally, mRNA 
underwent reverse transcription at 48 °C for 45 min which was followed by 2 min at 
94 to denature the AMV reverse transcriptase. This was followed by 20-28 cycles 
of PGR, including denaturation of double strand DNA at 9 4 � C for 30 sec，annealing 
of primer onto DNA at 48-65 for 1 min and extension of annealed primer at 68 
for 2 min. The RT-PCR procedure was completed by an additional 7 min of extension 
at 68 Blank control comprising of water instead of RNA was included for each 
primer on each occasion. PGR products were separated by electrophoresis in 2% (w/v) 
agarose gel stained with 5% (v/v) ethidium bromide (Invitrogen, Inc.), which was 
then visualized under ultra-violet transillumination and recorded photographically 
using the software GeneSnap (Syngene Americas, Frederick, MD，USA). 
Confirmation of identity of RT-PCR products 
Restriction fragment length polymorphism (RFLP) 
Complementary DNA (cDNA) of rat 3p-HSD and mouse LI9 were digested by 
Hinfl. Rat P450cll |3 cDNA, mouse Sp-HSD cDNA and 11 P-HSD cDNA were 
digested by Bsll. Rat 18S cDNA was digested by DpnI. Mouse P450cll |3 was 
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digested by Haelll. Rat P450scc cDNA, rat P450c21 cDNA, rat l ip-HSD cDNA and 
mouse P450SCC cDNA were digested by Mspl. Mouse P450c21 was digested by Ndel. 
Reaction mixture was prepared by adding 5 |il cDNA product from RT-PCR, 5 units 
of restriction enzymes, 1 |jJ of restriction enzyme buffer in a total volume of 10 )j.l 
made up by water. The mixture was incubated in 37 water bath overnight. It was 
then separated by electrophoresis in 2% (w/v) agarose gel stained with 5% (v/v) 
ethidium bromide, which was then visualized under ultra-violet transillumination and 
recorded photographically using the GeneSnap software (Syngene Americas). 
Direct sequencing 
RT-PCR products of steroidogenic enzyme genes were separated in 2% (v/v) 
agarose gel stained with 5% (v/v) ethidium bromide and purified by QIAquick gel 
extraction kit (Qiagen). Their sizes were checked by agarose gel electrophoresis. 
The sequencing PGR was then performed in a 10-|il reaction volume containing 4 |j,l 
BigDye Terminator ready reaction mix (Applied Biosystems), 5 |aM forward primer 
and 3-5 \x\ of the purified cDNA. The reaction involved initial denaturation at 96 °C 
for 1 min; 25 cycles of 96 for 10 sec, 50 for 5 sec and 60 for 4 min. The 
fluorescein-labelled DNA products were purified by passing through a spinning 
column packed with 1 ml 6% (w/v) Sephadex G50 gel and centrifuged at 1,100 x g 
for 2 min to remove excessive dye terminator, which interfere with base calling. The 
purified fluorescein-labelled DNA was mixed with an equal volume of Hi-Di 
formamide (Applied Biosystems) and electrophoresis was performed on an ABI Prism 
3100 genetic analyzer (Applied Biosystems). The sequences obtained were compared 
with the published sequences. 
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i. Steroidogenic enzyme mRNA expression in rat and mouse pituitary 
Male Sprague-Dawley rats at 6-10 weeks of age and weighing 200-250 g were 
obtained from LASEC and maintained in the animal holding room in the Prince of 
Wales Hospital (PWH). The animals had access to tap water and rat chow ad libitum. 
After three days they were sacrificed and the tissues, such as adrenal, pituitary, 
hypothalamus, cerebral cortex, cerebellum, liver and testis were removed for mRNA 
extraction and RT-PCR. P-actin was used as an internal control to confirm the 
integrity of the mRNA used. The identity of the RT-PCR product was confirmed by 
RFLP and direct sequencing. 
ii. Effects of hormonal treatments on weights of body, adrenal glands and testis, 
and steroidogenic enzyme mRNA expression in rats 
Male Sprague-Dawley rats, 10-12 weeks of age and weighing 350-450 g were 
divided into four groups of 4 animals. Group 1 was injected with 5 dexamethasone 
per 100 g body weight; Group 2 was injected with 0.25 ng testosterone per 100 g 
body weight; Group 3 was injected with 5 |ag dexamethasone and 0.25 ng testosterone 
per 100 g body weight; and Group 4 received 100 jil vehicle only. The steroids were 
dissolved in 0.1 ml vehicle, which was peanut oil. The animals were injected daily for 
3 weeks. The animals were weighed on the and day of treatment. At the 
end of the treatment, the animals were sacrificed by stunning and cervical dislocation. 
Adrenals, pituitary glands, and testes were removed. Adrenal glands and testes were 
weighed immediately. The adrenal and pituitary glands were then processed for 
mRNA extraction and subsequent RT-PCR. The RT-PCR conditions were optimized 
by titrating the number of PGR cycles - 20, 22, 24, 26 and 28, and RNA 
concentrations - 0.1, 1 and 10 ng RNA / \i\ reaction mix for each steroidogenic 
enzyme mRNA for each sample independently. RT-PCR of 18S ribosomal RNA was 
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also performed to confirm the integrity of the mRNA, and to correct for the variation 
in the amount of RNA in different samples. After capturing the gel images under 
ultraviolet transillumination, the intensities of the bands were measured using the 
Quantity One software (Bio-Rad Laboratories, Inc., Hercules, CA, USA). 
in. Effects of adrenalectomy and/or orchidectomy on the expression of steroidogenic 
enzyme mRNAs in rat pituitary 
Male Sprague-Dawley rats at 6-10 weeks of age and weighing 200-250 g 
underwent orchidectomy and/or adrenalectomy, which were performed by a 
veterinary surgeon in LASEC. The animals were divided into four groups of 2 
animals. Group 1 was adrenalectomized; Group 2 was orchidectomized; Group 3 had 
received both adrenalectomy and orchidectomy and Group 4 was not operated on. The 
animals were allowed to recover for 5 days at LASEC before being transferred to the 
animal holding room in PWH. The animals had free access to tap water and rat chow. 
The adrenalectomized animals were provided with 0.9 % (w/v) NaCl solution instead 
of water. After one week, the animals were sacrificed and tissues collected for mRNA 
extraction and RT-PCR. The optimization of RT-PCR conditions, RNA concentrations 
and monitoring of recovery were as described above. 
c. In vitro experiments 
Cell culture 
Rat anterior pituitary cells (RC-4B/C) were cultured at 37 in 5% CO2 
humidified incubator in a medium comprising 45% (v/v) DMEM with 1.5 g/L sodium 
bicarbonate and 4.5 g/L glucose, 45% (v/v) alpha MEM containing 1 g/L glucose and 
10% (v/v) heat-inactivated dialysed FBS, supplemented with 0.01 mM non-essential 
amino acids, 15 mM HEPES, 0.2 mg/ml BSA, 2.5 ng/ml EGF，4 mM L-gliitamine and 
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antibiotic-antimycotic (100 U/ml penicillin G, 100 |Lig/ml streptomycin and 250 ng/ml 
amphotericin B). Mouse corticotroph cells (AtT-20) were cultured at 3 7 � C in 5% CO2 
humidified incubator in 82.5% (v/v) Ham's F12K medium, 15% (v/v) horse serum 
and 2.5% (v/v) heat-inactivated dialysed FBS, supplemented with 1.5 g/L sodium 
bicarbonate, 2 mM L-glutamine and the above antibiotic/antimycotic mixture. 
Upon reaching confluency, the cells were disaggregated with 0.53 mM 
trypsin-EDTA solution and subcultured. 
Preparation of cells for cAMP assay 
Generally, cells were seeded in quadruplicate in 24-well culture plates at a 
density of 66,000 cells/ well/ ml of growth medium and preincubated for 48 hr. Just 
before the treatments, growth medium was aspirated and the cells were washed with 
HBSS containing calcium and magnesium. After the treatments (specified below), the 
medium from each well was collected and stored at -20 until further use. The cells 
remaining in the wells were lysed with HCl/EtOH mixture for cAMP extraction and 
determination. 
RIA ofcAMP 
Following treatment procedure, cells in the 24-well culture plate were lysed with 
1.7% HCl/EtOH and kept at -20 overnight. The lysed cells were dried in a vacuum 
concentrator (Savant SpeedVaC SVC 100, Thermo Electron Corp., Milford, MA, USA) 
connected to a freeze dryer (BOC Edwards Pharmaceutical Systems, Tonawanda, NY, 
USA) at -40 for 4 hr. The dried extracts were reconstituted in 125 of cAMP 
assay buffer. Fifty of the extract was mixed with 50 |il tritiated cAMP tracer and 
100 1^1 cAMP binding protein. The mixture was incubated at 4 °C for 3 hr. After 
incubation, 500 [xl charcoal absorbent was added per tube and mixed. The mixture 
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was centrifuged at 3500 rpm at 4°C for 25 min to separate bound from free cAMP. 
The supernatant containing the bound cAMP was decanted into 5 ml of scintillation 
cocktail and mixed vigorously. Radioactivity was measured in a Beckman LS6500 
liquid scintillation counter (Beckman Coulter, Inc.). 
Preparation of cells for mRNA expression determination 
Cells were seeded in triplicate in 35-mm culture dish at 300,000 cells/dish/4 ml 
growth medium and preincubated for 48 hr. Just before the treatments, growth 
medium was aspirated and the cells were washed with HBSS containing calcium and 
magnesium. After the treatments (specified below), the culture media were removed， 
and lysis buffer added directly to the dish. Total RNA was extracted with RNeasy 
Mini total RNA isolation kit (Qiagen) following the manufacturer's instruction. Total 
RNA were extracted and subjected to RT-PCR. 
/. Effects of CRF and forskolin on cAMP production in mouse and rat pituitary 
cell-lines 
RC-4B/C and AtT-20 cells were incubated with 250 HPBR solution containing 
either, (i) 0.01 |iM to 1 |iM CRF in 0.5%(w/v) BSA; or (ii) 0.001 |iM - 10 |iM 
forskolin in 0.5% (w/v) BSA and 1% (v/v) DMSO) for 2 hr in a 3 7 � C 5% CO2 
humidified incubator. 
ii. Expression of steroidogenic enzyme mRNAs in rat and mouse pituitary cell-lines 
RC-4B/C and AtT-20 cells were grown in 60 mm culture dishes to 80% 
confluency. After removing the culture medium, the cells in the dishes were treated 
with lysis buffer provided in the RNeasy Mini total RNA isolation kit (Qiagen). Total 
RNA was extracted for RT-PCR. 
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Hi- Effects of CRF on the expression of steroidogenic enzyme mRNAs in rat and mouse 
pituitary cell-lines 
RC-4B/C and AtT-20 cells were incubated in 0.6 ml HPBR solution containing 1 
CRF [0.5% (w/v) BSA] for 2 hr in a 37 5% CO2 humidified incubator. After 
removing the culture medium, the cells in the dishes were treated with lysis buffer 
provided in the RNeasy Mini total RNA isolation kit (Qiagen). Total RNA was 
extracted for RT-PCR. The optimization of RT-PCR conditions, RNA concentrations 
and monitoring of recovery were as described above. 
d. Statistical analysis 
The data are presented as mean 土 SEM. They were analyzed using 
Mann-Whitney test with the software GraphPad Prism (GraphPad Software Inc., San 




a. In vivo experiments 
/. Steroidogenic enzyme mRNA expression in rat and mouse pituitary 
The mRNAs for P450scc, 3|3-HSD, CYP21, CYPl lBl and 11(3-HSD-1 were 
detected in the rat pituitary along with the adrenal gland, cerebellum, cerebral cortex 
and hypothalamus (Figure 3.1). However, the RT-PCR products for CYP11B2 in the 
pituitary were represented by 700 and 850 bp bands, which differed from the 323 bp 
band expressed in the adrenal (Figure 3.2). Messenger RNA expression for CYP17 
was observed only in the Leydig cell and liver, but not in the adrenal gland, 
hypothalamus and pituitary (Figure 3.3). In the mouse, only 3p-HSD and llp-HSD-1 
mRNAs were detected in both the adrenal and pituitary gland, whereas bands with the 
expected sizes for P450scc, CYP21 and CYPl lBl were detected in the adrenal only 




Genes Tissues Expected product 
M | A | C e | C o | H | p | L | B | M size (bp) 
P450SCC • B P I M I I M H i n V I F I 559 
3P-HSD I � _H H P i l l ' P i i j • � • ^ 
CYP21 ^ 
E B M M W l i M M ^ K j  
CYPllBl ^^mmmrn^mmmmmm^^^m 323 
11 P-HSD-1 ^ 
Figure 3.1 The RT-PCR products for P450scc, 3p-HSD, CYP21, C Y P l l B l , 
11 P-HSD-1 and P-actin in various rat tissues, including adrenal (A), cerebellum (Ce), 
cerebral cortex (Co), hypothalamus (H), pituitary (P) and liver (L). The brightest band 
in lane M represents 600 bp DNA marker and lane B is a blank control. 
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Genes Tissues Expected product 
M | A | C e | C o | H | p | L | B 一 size (bp) 
CYP11B2 ^ ^ i ^ H H m m m H H ^ 
Figure 3.2 The RT-PCR products for CYP11B2 in rat tissues, including adrenal (A), 
cerebellum (Ce), cerebral cortex (Co), hypothalamus (H), pituitary (P) and liver (L). 
The brightest band in lane M represents 600 bp DNA marker and lane B is a blank 
control. The band with the expected size in the adrenal is indicated by the arrow. 
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Genes Tissues product size (bp) 
M I A I Ley I Liv I H I P I B 
C Y P 1 7 1 1 m u ^ ^ ^ m m | 
Figure 3.3 The RT-PCR products for CYP 17 in rat tissues, including adrenal (A), 
Leydig cell (Ley), liver (Liv), hypothalamus (H) and pituitary (P). The brightest and 




M A P B A I P I B 
Genes P450scc 3p-HSD 
Product size (bp) 947 99 
Genes “ CYP21 CYPllBl 
Product size (bp) 451 243 
Genes “ lip-HSD-1 LI 9 — 
Product size (bp) 368 405 
Figure 3.4 The RT-PCR products for P450scc, 3p-HSD，CYPllBl, l lp-HSD-1 and 
LI9 in mouse adrenal (A) and pituitary (P). The brightest band in lane M represents 
500 bp DNA marker and lane B is a blank control. 
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The DNA fragments derived from the mRNAs expressed in rat and mouse 
adrenal and pituitary gland following restriction fragment length polymorphism 
(RFLP) are shown in figure 3.5. In the rat, the digested fragments for P450scc, 
3P-HSD, CYP21, lip-HSD-1 and 18S rRNA yielded similar sized products from both 
the adrenal and pituitary gland. In case of the pituitary CYPl lB l , the RFLP resulted 
in smearing. For mouse adrenal and pituitary tissues, the fragments of expected sizes 
were observed for 3P-HSD, lip-HSD-1, and L19. In the case of P450scc, the 
expected fragment only occurred in the adrenal sample. Similar to the rat, DNA 
fragments derived from RT-PCR of CYPl lB l mRNA from mouse adrenal and 
pituitary glands also smeared. Again, P450scc was not expressed in the mouse 
pituitary, as shown in figure 3.4. 
Direct sequencing of RT-PCR products for P450scc, 3P-HSD, CYP21, CYPl lB l 
and lip-HSD-1 in rat pituitary tissue, and 3p-HSD and lip-HSD-1 in mouse pituitary 
tissue yielded greater than 90% similarity to the published sequences (Appendix 1). 
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Tissues M A | P 一 A | P ~ ^ | P A | P A | P | A | P 
Genes P45Qscc 3p-HSD CYP21 C Y P l l B l lip-HSD-1 18S 
Tissues M A P A A P A P A P 
Genes P450scc 3P-HSD C Y P l l B l 11|3-HSD-1 L19  
Figure 3.5 DNA fragments for rat and mouse adrenal (A) and pituitary (P) gland 
P450SCC, 3P-HSD, CYP21, C Y P l l B l , l lp -HSDl and 18S rRNA/L19 mRNAs after 
RFLR The brightest in lane M represents 50 bp DNA marker. 
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Table 3.1 Restriction enzymes used and the resultant DNA fragments (bp) of P450scc, 
3P-HSD, CYP21, C Y P l l B l , l lp-HSD-1 and 18S/L19 in rat and mouse adrenal and 
pituitary glands. 
Restriction enzymes / Size of DNA fragments (bp) 
Genes Hinfl BslI Dpiil Haelll Mspl Ndel 
Rat P450SCC - - - - 179/370 -
3P-HSD 280/293 - - - ： -
— C Y P 2 1 - 一 - - — - 89/91 -
C Y P l l B l - 88/235 - - ：  
“ l lp-HSD-1 “ - ： ： “ - 164/296 -
- - 56/120 - - ^  
Mouse P450SCC - - ： - 334/613 -
: 3P-HSD - 2/97 - ： ： ： 
_ _ _ _ _ _ _ CYP21 - ： ： ： “ 顶 71 
• 二 - - - 27/109- - -
~ l lp-HSD-1 _ _ _ _ _ 178/190 - ： ： ： 




ii- Effects of hormonal treatments on weights of body, adrenal glands and testis, and 
steroidogenic enzyme mRNA expression in rats 
Compared to the control rats injected with the vehicle only, injecting 
dexamethasone or dexamethasone combined with testosterone for 3 weeks 
significantly (p<0.05, Mann-Whitney test) retarded the increase in body weight 
(Figure 3.6). There was no significant difference in body weights of rats treated with 
testosterone and control rats, at the start, mid-way and at the end of study period. 
Whilst the testosterone-treated and control rats gained significant weight (p<0.05, 
Mann-Whitney test) over the three week period, the animals treated with 
dexamethasone or dexamethasone combined with testosterone did not gain weight. 
The weights of adrenal glands (Figure 3.7a) were significantly (p<0.05, 
Mann-Whitney test) lower in rats treated with dexamethasone (2.4-fold) or 
dexamethasone and testosterone combination (2.1-fold) than the control group. 
Adrenal weights of rats treated with testosterone alone were not different from control 
animals. None of the treatments caused a significant change in the weight of testes 
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Figure 3.6 Body weight (mean 士 SEM) of rats (n = 4) after treatment with 
dexamethasone (square), testosterone (triangle) or dexamethasone + testosterone 
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Figure 3.7 Weight (mean 士 SEM) of adrenal glands (a) and testes (b) in rats after 
treatment with dexamethasone (Dex), testosterone (Testo), both (Dex + Testo) or the 
vehicle (n = 4). Asterisks represent significant (p<0.05) difference for comparison 
using Mann-Whitney test. 
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Figure 3.8 a to d show the expression of P450scc, 3p-HSD，CYP21 and 
C Y P l l B l mRNA, respectively in adrenal glands of rats following treatment with 
dexamethasone, testosterone, dexamethasone combined with testosterone and vehicle 
only. The expression of C Y P l l B l (Figure 3.8d) was significantly (p<0.05, 
Mann-Whitney test) down-regulated to 4% and 6% of the control following treatment 
with dexamethasone or dexamethasone combined with testosterone, respectively. 
However, the levels of expression of P450scc, 3|3-HSD，CYP21 and C Y P l l B l , 
normalized against 18S rRNA as the internal control, were not altered following 
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Figure 3.8 a and b. Messenger RNA expression levels (mean 士 SEM) for (a) P450scc 
and (b) 3P-HSD in adrenal glands (n = 4) of rats after treatment with dexamethasone 
(Dex), testosterone (Testo), both (Dex + Testo) or the vehicle (control). The 
expression levels of genes are normalized to the expression of 18S rRNA in the 
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Figure 3.8 c and d. Messenger RNA expression levels (mean 士 SEM) for (c) 
CYP21 and (d) C Y P l l B l in adrenal glands (n = 4) of rats after treatment with 
dexamethasone (Dex), testosterone (Testo), both (Dex + Testo) or the vehicle (control). 
The expression levels of genes are normalized to the expression of 18S rRNA in the 
respective treatment group, and are expressed relative to the basal expression in 
vehicle-injected controls. Asterisks represent significant (p<0.05) difference for 
comparison using Mann-Whitney test. 
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Figure 3.9 a to f show the expression of LH-P, POMC, P450scc, 3(3-HSD, 
CYP21 and C Y P l l B l mRNA, respectively in pituitary glands of rats following 
treatment with dexamethasone, testosterone, dexamethasone combined with 
testosterone or the vehicle only. The steroid hormone treatments had no effect on the 
mRNA expression of the tropic hormones (LH-P and POMC) and the steroidogenic 
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Figure 3.9 a and b. Expression levels of mRNA (mean 士 SEM) of LH-P (a) and 
POMC (b) in pituitary glands (n = 4) of rats after treatment with dexamethasone 
(Dex), testosterone (Testo), both (Dex + Testo) or the in vehicle-injected controls. The 
expression levels of genes are normalized against the expression of 18S rRNA in the 
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Figure 3.9 c and d. Expression levels of mRNA (mean 士 SEM) of 18S rRNA (c) 
P450SCC and (d) 3p-HSD in pituitary glands (n = 4) of rats after treatment with 
dexamethasone (Dex), testosterone (Testo), both (Dex + Testo) or in the 
vehicle-injected controls. The expression levels of genes are normalized against the 
expression of 18S rRNA in the respective treatment group, and are expressed relative 
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Figure 3.9 e and f. Expression levels of mRNA (mean 士 SEM) of CYP21 (e) and 
C Y P l l B l (f) in pituitary glands (n = 4) or rats after treatment with dexamethasone 
(Dex), testosterone (Testo), both (Dex + Testo) or in the vehicle-injected controls. The 
expression levels of genes are normalized against the expression of 18S rRNA in the 




in. Effects of adrenalectomy and/or orchidectomy on the expression of steroidogenic 
enzyme mRNAs in rat pituitary 
The effects of adrenalectomy and/or orchidectomy on the expression of mRNAs 
for the tropic hormones LH-P subunit and POMC, and P450scc, 3P-HSD, CYP21, 
C Y P l l B l and 11 P-HSD-1 in the pituitary glands are shown in figure 3.10 a to f, 
respectively. Although the sample size was not large enough for a statistical analysis, 
orchidectomy augmented LH-p subunit expression for 70% (figure 3.9a), which also 
occurred in rats with combined adrenalectomy. On the other hand, adrenalectomy 
caused a 30% increase in POMC expression (figure 3.9b), but this effect was not 
replicated in animals with combined orchidectomy. With the exception of high mRNA 
expressions of P450scc, 3P-HSD, CYP21 and CYPl lBl in one rat in the 
orchidectomized group, adrenalectomy and/or orchidectomy had no significant effect 
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Figure 3.10 a and b. Expression levels of LH-p (a) and POMC (b) mRNA in the 
pituitary gland shown individually for each pair of rats following adrenalectomy 
(ADX), orchidectomy (ODX) or both (ADX + ODX), and in the controls. The 
expression levels of genes are normalized against the expression of 18S rRNA in the 
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Figure 3.10 c and d. Expression levels of mRNA of (c) P450scc and (d) 3p-HSD in 
the pituitary gland shown individually for each pair of rats following adrenalectomy 
(ADX), orchidectomy (ODX) or both (ADX + ODX) and in the controls. The 
expression levels of genes are normalized against the expression of 18S rRNA in the 
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Figure 3.10 e and f. Expression levels of mRNA of (e) CYP21 and (f) CYPl lBl in 
the pituitary gland shown individually for each pair of rats following adrenalectomy 
(ADX), orchidectomy (ODX) or both (ADX + ODX) and in the controls. The 
expression levels of genes are normalized against the expression of 18S rRNA in the 




b. In vitro experiments 
i- Effects of CRF and forskolin on cAMP production in mouse and rat pituitary 
cell-lines 
Cyclic AMP production in response to CRF 
The intracellular cAMP levels rose in a dose-dependent manner following CRF 
stimulation in AtT-20 cells (figure 3.11a). The increase was significant (p<0.05, 
Mann-Whitney test) at CRF concentrations from 0.25 \iM to 0.5 |aM, rising to 6-fold 
above basal, in response to 0.5 i^ M of CRF. However, at 1.0 |_iM of CRF and above, 
the cAMP production was similar to the unstimulated state. Similarly, in RC-4B/C 
cells (figure 3.11b), cAMP levels rose significantly (p<0.05, Mann-Whitney test) in 
presence of CRF from 0.125 |.iM to 0.25 |iM (3-fold above basal), followed by a drop 
from 0.5 ^M to 1 fiM of CRF. However at 2 i^M CRF concentration, cAMP level was 
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Figure 3.11 Cyclic AMP production (mean 土 SEM，n = 4) in response to increasing 
concentrations of CRF in AtT-20 (a) and RC-4B/C (b) cells. 
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Cyclic AMP production in response to forskolin 
The two pituitary cell lines displayed different cAMP response to forskolin. 
Whilst cAMP level increased dose-dependently in both AtT-20 (figure 3.12a) and 
RC-4B/C (figure 3.12b) cells, the magnitude of increase was significantly greater in 
the latter cell line. At basal condition (no forskolin), both cell-lines produced very low 
level of cAMP (<0.5 pmol/ 66,000 cells). But in presence of 10 pM forskolin, the 










•si. 5- ^ ^ 
§ 3 � ^ ^ 
E 2 -
O'T 1 1 1 1 1 r~I 1 1 1— 






O-T I 1 1 1—I 1 1 1 1 1 
0 1 2 3 4 5 6 7 8 9 10 
Forskolin (fiM) 
Figure 3.12 Cyclic AMP production (mean 士 SEM, n = 4) in response to increasing 
concentration of forskolin AtT-20 (a) and RC-4B/C (b). 
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ii. Expression of steroidogenic enzyme mRNAs in rat and mouse pituitary cell-lines 
The mouse corticotroph cell-line AtT-20 expressed only 3p-HSD mRNAs, which 
corresponded to the expected band sizes of 99 bp (Figure 3.13). Whilst band of 200 
bp appeared for P450scc mRNA in the cell-line, it was different from the previously 
published sizes of 947 bp (Greco and Payne 1994). No bands for CYP21 and 
CYP l l B l mRNA were detected in the cell-line. 
I KPI 
w^mmm 
Genes M A B | C | D | ~ ~ 
Expected product sizes (bp) 947 99 243 451 304 
Figure 3.13 RT-PCR products ofP450scc (A), 3p-HSD (B), CYPl lB l (C)，CYP21 (D) 
and LI9 (E) in mouse corticotroph AtT-20 cell-line. The brightest band in lane M 
corresponds to molecular size of 500 bp. 
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The rat pituitary cell-line RC-4B/C expressed mRNAs for P450scc, 3P-HSD and 
l ip-HSD-1 (Figure 3.14) of expected band sizes. The CYPl lBl mRNA detected had 
a band size of 700 bp, which was different from 323 bp reported previously (Ye et al. 
2003) 
I ^ ^ ^ ^ H H H ^ : 减 I 镇 機 • 
Genes M A B C D E F 
Product 549 573 323 645 460 644 
sizes (bp) 
Figure 3.14 RT-PCR products of P450scc (A), 3p-HSD (B), CYPl lBl (C), CYP17 
(D), l ip-HSD-1 (E) and P-actin (F) in rat pituitary RC-4B/C cell-line. The brightest 
band in lane M corresponds to molecular size of 500 bp. 
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Hi. Effects of CRF on the expression of steroidogenic enzyme mRNAs in rat and mouse 
pituitary cell-lines 
Figure 3.15 shows the effect of CRF on the expression of steroidogenic enzyme 
mRNAs in AtT-20 and RC-4B/C cells respectively, which was repeated once. 
Incubation of AtT-20 cells with CRF slightly augmented the mRNA level of 3p-HSD 
only, and had no effect on 3(3-HSD and P450scc mRNA levels in RC-4B/C cells. 
Cell-lines Genes Product size  
^  
AtT-20 3P-HSD ^ 
RC-4B/C 3P-HSD ^ 
549 l^n 
Control I CRF 
Figure 3.15 Expression of 3P-HSD in AtT-20, and 3P-HSD and P450scc in RC-4B/C 




This project arose from an enigmatic observation of higher Cortisol levels in the 
inferior petrosal sinus (IPS) effluent of Gushing's disease patients undergoing 
lateralization procedure for localization of microadenomas following CRH 
stimulation (Panesar et al, unpublished data). One possible cause for such an 
observation is the de novo synthesis of steroid hormone in the adenomatous nature of 
pituitary gland, which has not yet been reported. It has been known for the past two 
decades that brain tissues are capable of synthesizing steroids — termed neurosteroids, 
which to all intents are steroid hormones as synthesized in the conventional 
steroidogenic organs, namely gonads and adrenal cortex, but apparently function as 
neurotransmitters in the brain (Corpechot et al 1983). Besides the brain, ectopic 
steroidogenesis has also been described in the heart (Young et al 2001) and thymus 
(Lechner et al. 2000). Therefore, this study was undertaken to find out if normal 
pituitary gland has the potential to synthesize steroids hormones. Although various 
regions of brain have been studied in connection with steroidogenesis, there is a 
paucity of studies on the pituitary. Therefore the main aim of this project was to 
examine the expression of mRNAs for steroidogenic enzyme in normal pituitary and 
their regulation. 
This project commenced with the detection of steroidogenic enzyme mRNA in 
normal animals. In male rats aged 6-10 weeks, mRNAs for P450scc, 3P-HSD, CYP21, 
C Y P l l B l and l ip-HSD-1 were detected in the pituitaries by RT-PCR (Figure 3.1) 
while the mRNAs for CYP 17 and CYP11B2 were absent (Figure 3.2 and 3.3). This 
study thus supports previous finding regarding the expression of 3p-HSD (Vidal et al. 
2000) and l ip-HSD-1 (Korbonits et al. 2001) mRNAs in the rat pituitary. But in 
normal mouse aged 20-24 weeks, only 3p-HSD and 11(3-HSD mRNA expressions 
were detected in the pituitaries, while the mRNAs for P450scc, CYP21 and C Y P l l B l 
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were absent (Figure 3.4), 
The authenticity of the mRNAs for steroidogenic enzymes expressed in the rat 
and mouse pituitaries were examined by comparing the band sizes of the RT-PCR 
products with those of the positive control organs, including the rat adrenal gland, 
cerebellum, cerebral cortex and hypothalamus. Adrenal gland is the primary site of 
steroidogenesis, particularly glucocorticoids and mineralocorticoids, and expresses 
mRNA for P450scc, 3p-HSD, CYP21，CYPllBl, CYP11B2 and 11 p-HSD-1 in rat 
(Lehoux et al. 1998) (Oaks and Raff 1995). Cerebellum and cerebral cortex are two 
major sites in the brain recently found to possess the ability to synthesize steroids 
expressing mRNAs for P450scc, 3P-HSD, (Kohchi et al 1998) C Y P l l B l and 
CYP11B2 (Rudolph et al 2000). Hypothalamus is an extension of the brain and 
regulates pituitary secretion, where the expressions of P450scc, 3p-HSD (Nishida et 
al 2005) and l ip-HSD-1 (Moisan et al 1990) mRNAs have been reported. RT-PCR 
bands with identical sizes to the aforementioned control tissues were thus observed 
either for all or some steroidogenic enzymes in the rat and mouse pituitary glands. 
Furthermore, the expressions of CYP21 mRNA in the cerebellum and cerebral cortex, 
and CYP21 and C Y P l l B l mRNA in hypothalamus were also found, which have not 
been previously reported. Rat adrenal gland produces corticosterone, which lacks 
17a-hydoxyl group, instead of Cortisol because of the absence of CYP17. CYP17 is 
present only in gonads and liver of rats (Katagiri et al 1998). However, one report has 
shown its expression in the rat adrenal, without explaining such discrepancy 
(Stromstedt and Waterman 1995). In the present study, the expression of CYP17 
mRNA was detected only in the testis and liver, but not in the adrenal, hypothalamus 
and pituitary, which is in agreement with previous studies. As for CYP11B2 mRNA 
expression, despite previous reports on its presence in the adrenal (Bassett et al 2004)， 
cerebral cortex and cerebellum (Rudolph et al 2000), RT-PCR product with the 
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expected band size of 323 bp was only observed in the adrenal, but not in the brain 
tissues. The fact that the primers used produced the expected product from adrenal 
extract would rule against wrong primers being used. The absence of CYP 11B2 PGR 
product in cerebral cortex and cerebellum could be due to the low level of 
transcription. Bands of larger sizes were observed in cerebral cortex, cerebellum, 
hypothalamus and pituitary. The difference in band sizes may be due to the low level 
or absence of CYP 11B2 transcripts so that the primers may have annealed to other 
mRNA. One possible candidate may be the mRNA for XLa protein, which has 69 and 
75% similarity to primers for CYP11B2 mRNA. No further investigations were 
conducted on CYP 17 and CYP11B2. 
In the mouse, the adrenal gland was used as the positive control organ, which 
expresses steroidogenic enzymes such as P450scc, 3p-HSD, CYP21, C Y P l l B l and 
l ip-HSD-1 (Payne and Hales 2004). Whilst the RT-PCR products with the expected 
band sizes were detected for the aforementioned enzymes in the mouse adrenal 
(Figure 3.3), the pituitary gland only yielded bands of expected sizes for 3P-HSD and 
l ip-HSD. A band with larger than expected size was detected for C Y P l l B l in the 
pituitary. This could probably be due to the absence of C Y P l l B l transcript in the 
pituitary and binding of its primers to other gene transcripts. No further investigations 
were conducted on P450scc, CYP21 and C Y P l l B l in mouse. 
The identities of RT-PCR products of steroidogenic enzyme mRNA from the rat 
and mouse pituitary glands were further confirmed qualitatively by restriction 
fragment length polymorphism (RFLP) (Figure 3.5) and direct sequencing (Appendix 
1). In RFLP, cDNAs from pituitary are spliced at specific sites by the restriction 
enzymes resulting in DNA sub-fragments with definite sizes and are compared to 
fragments from known tissues such as the adrenal gland. Whilst the RFLP analyses of 
P450SCC, 3P-HSD, CYP21 and 1 lp-HSD-1 mRNA from rat pituitary and 3|3-HSD and 
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11 P-HSD-1 from mouse pituitary yielded DNA fragments similar to those from the 
adrenal gland, that for CYPl lB l from rat pituitary showed smearing. This may be 
due to the low expression level of CYPl lBl transcript, as well as non-specific 
RT-PCR products, e.g. from XLa, which may have yielded variable length of DNA 
fragments following RFLP that caused the smearing. 
Direct sequencing of the RT-PCR products of P450scc, 3P-HSD, CYP21, 
C Y P l l B l and l lp-HSD-l mRNA in rat pituitary and 3P-HSD and llp-HSD-1 in 
mouse pituitary yielded over 90% sequence similarity with the published sequences. 
No perfect match was obtained which may be due the limited fidelity of the AMV 
reverse transcriptase used in RT-PCR, which allows extension despite base-pair 
mismatching (Yu and Goodman 1992). 
An attempt was also made to study the regulatory mechanism of steroidogenic 
enzyme mRNA expression in the rat pituitary. It was hypothesized that steroidogenic 
enzyme expressions are regulated through the same mechanisms as those for 
steroidogenic enzymes in the conventional steroid hormone-producing organs such as 
the adrenal gland, with the involvement of CRF and ACTH. CRF was thought to be a 
likely regulator of pituitary steroidogenesis since it stimulates ACTH secretion from 
the pituitary and is also reported to stimulate steroidogenesis directly in adrenal 
medulla (Ehrhart-Bornstein et al. 1998). As for ACTH, because its levels are higher in 
the pituitary than in peripheral circulation, and its role in stimulating adrenal 
steroidogenesis, the potential for ACTH acting in collaboration with CRF in 
autocrine/paracrine fashion in stimulating pituitary steroidogenesis seems feasible. 
Furthermore, endogenous or exogenous glucocorticoids may influence the pituitary 
steroidogenic enzyme mRNA expressions through their feedback mechanism. Apart 
from the prominent inhibition of hypothalamic and pituitary secretions, 
glucocorticoids enhance the transcription of 3p-HSD-II in the adrenal by binding to 
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the Stat5 response element (Stat5RE) (Feltus et al 2002). So how would 
glucocorticoids act in another possible steroidogenic organ, such as the pituitary, 
which is normally a target for inhibitory action? Will they impede the expression of 
steroidogenic enzymes, as they inactivate the positive POMC transcription factor 
(Herman and Majzoub 2002), or enhance it by binding to StatSRE, as happens in the 
adrenal (Feltus et al. 2002)? The manipulation of the conventional regulatory 
mechanisms involving tropic hormones in steroidogenesis in gonads and adrenal 
glands were tested in the rat pituitary. Tropic hormone levels were altered by indirect 
approaches. They were either down-regulated by daily injection of exogenous steroid 
hormones such as dexamethasone and testosterone for 3 weeks; or up-regulated by the 
removal of steroidogenic organs, i.e. adrenal gland and testis. 
Male rats aged 10-12 weeks were treated either with dexamethasone or 
testosterone, or combination of both for 3 weeks. The efficacy of treatments was 
examined by the effects on weights of body, adrenal and testis and the mRNA 
expression levels of LH-P and POMC in the pituitary. Dexamethasone is an analog of 
Cortisol or corticosterone, the catabolic hormones that induces body weight loss, and 
suppresses POMC expression in pituitary, thus lowering ACTH secretion. POMC 
expression in the pituitary was suppressed one day after dexamethasone injection and 
sustained for days in a delayed feedback response (Keller-Wood and Dallman 1984). 
ACTH is the predominant tropic factor for the adrenal glands (Gill 1979). The lack of 
ACTH thus hinders the growth and repair of the adrenal, resulting in adrenal atrophy, 
and should lead to decreased adrenal steroidogenesis including the transcription of 
steroidogenic enzymes. On the other hand, testosterone is an anabolic hormone 
(Herbst and Bhasin 2004) that suppresses pituitary LH expression and secretion. 
Chronic injection of testosterone for 5 days reduces the serum LH level, while not 
altering the body and testis weight (Dewan et al. 2000). Treatment with 
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dexamethasone alone or combined with testosterone produced the following results. 
Firstly, the body weights of dexamethasone-treated rats remained constant throughout 
the treatment, while those treated with testosterone, and the control rats had a 20% 
increase in body weight (Figure 3.6). This is not surprising considering 
dexamethasone is essentially a catabolic hormone, whereas testosterone is an anabolic 
hormone. Secondly, the adrenal weights in the former two groups of rats were also 
significantly lower than the control group by about 100% (Figure 3.7a), most likely 
due to feedback inhibition of dexamethasone on ACTH release, while the weights of 
the adrenal glands in rats treated with testosterone alone were the same as the control 
rats. In addition, the expression of CYPl lB l was suppressed significantly in rats 
treated with dexamethasone and dexamethasone combined with testosterone by 96% 
and 94% respectively (Figure 3.8e). Despite the above indirect evidence of decreased 
ACTH release, no significant changes in the expression levels of other steroidogenic 
enzymes viz P450scc, 3p-HSD and CYP21 mRNAs were observed in the adrenal 
gland. Moreover, the expression of POMC in the pituitary was not altered after three 
weeks of dexamethasone injection (Figure 3.9b). By all account, treatment with 
dexamethasone should have reduced POMC expression in the pituitary, so the lack of 
suppression is surprising. A possible reason could be the extreme stress experienced 
by the rats during the slaughtering process (Autelitano 1998), thus resulting in the 
indistinguishable POMC expression levels across all treatment and control groups. On 
the other hand, treatment with testosterone alone did not result in significant 
difference in body or testis weights compared to the control group (Figure 3.7b). The 
results of body and testis weights agreed with the previous report (Dewan et al. 2000). 
Surprisingly again, testosterone treatment had no effect on LH-p expression level in 
the pituitary (Figure 3.9a), which should have been down-regulated. If one compares 
the dosage of testosterone in the present study (0.25 ng/100 g body weight) with that 
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used by Dewan et al. (10 mg/100 g body weight), it seems the dosage in current study 
was too low, which could account for the lack of response. Because of the ineffectual 
action of testosterone, combined injection of dexamethasone and testosterone could 
only bring about the effect of dexamethasone alone, but not those of the combined 
treatment. The effect of dexamethasone injection on altering the HPA axis activity can 
thus be confirmed, but the effect of testosterone on altering the HPG axis activity 
could not be confirmed. As far as the pituitary was concerned, mRNA expression for 
P450SCC，3P-HSD, CYP21 and C Y P l l B l in the pituitary was not altered by any of the 
hormonal treatments (Figure 3.9d to g). 
In an attempt to up-regulate the pituitary gland by surgically removing the organs 
that impose feedback on the HP axis, the efficacy of the treatment was verified by 
examining the expression levels of POMC and LH-(3 mRNA in the pituitary. The 
removal of adrenal should lead to the rise of hypothalamic CRF and pituitary ACTH 
level (Viau et al. 1999). On the other hand castration should lead to increased LHRH 
release from the hypothalamus, with resultant gonadotroph hyperplasia and inducing 
hypertrophy (Bhasin et al. 2002). There should also be increased expression of 
pituitary LH-p mRNA expression. In the adrenalectomised rats (Figure 3.10a and b), 
POMC expression in the pituitary was consistently raised by 30% while LH-p 
expression remained similar to the controls. In orchidectomized (ODX) rats, LH-P 
expression was consistently augmented for 70% while the change in POMC 
expression was not prominent. These agree with the previous findings (Bhasin et al. 
2002). However, in rats with combined adrenalectomy and orchidectomy, while the 
LH-P expression level was also augmented 70%, similar to ODX alone, the POMC 
expression, which should have risen, showed no prominent change. LH suppression of 
POMC expression as a way of crosstalk between the HPA and HPG axes has not been 
reported. It is generally regarded that steroid hormones form the backbone of HPG 
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and HPA regulation (Viau 2002), leaving the brain to be the most possible source of 
glucocorticoid that influences pituitary POMC expression. Indeed, the brain in 
adrenalectomized and orchidectomized rat is capable of producing active steroid 
hormones such as 5a-dehydroxyprogesterone (Corpechot et al 1993). All in all, it can 
be confirmed that the removal of adrenal and testis are effective in activating the HPA 
and HPG axis respectively. As far as the steroidogenic enzyme expression was 
concerned, with the exception of high mRNA expressions of P450scc, 3P-HSD, 
CYP21 and C Y P l l B l in one orchidectomized rat, adrenalectomy and/or 
orchidectomy had no significant effect on steroidogenic enzyme mRNA expression in 
the pituitary (Figure 3.9d to g). The extremely high level of expression in one of the 
rats from the orchidectomized group may be due to excessive stress during the 
handling process or due to experimental errors. 
From the in vivo experiments, neither the down- nor up-regulation of pituitary 
function resulted in significant change in the expression level of steroidogenic 
enzyme mRNA, including P450scc, 3P-HSD, CYP21 and CYPl lB l , in the rat 
pituitary. Although the sample sizes in these experiments were small, the results 
tentatively showed that CRF, ACTH and glucocorticoids did not change the level of 
steroidogenic enzyme expression in the pituitary. Therefore, it seems possible that 
these mRNA expressions are not necessarily regulated through the same mechanisms 
as those for steroidogenic enzymes in the conventional steroid hormone-producing 
organs. 
Because the in vivo study of the regulatory mechanism did not accomplish the 
expected results, and also because of the technical difficulties in handling and treating 
a large number of live animals, especially the involvement of veterinarian in surgical 
operations, this project was then shifted to the use of immortalized pituitary cell-lines, 
namely RC-4B/C and AtT-20 cell-lines. RC-4B/C is a rat cell-line which displays the 
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immunoreactivity for each of the anterior pituitary hormone-secreting cell types in the 
anterior pituitary (Polkowska et al 1991). AtT-20 is a mouse cell-line derived from 
corticotrophs with ACTH as its main secretory product (Ooi et al. 2004). The 
cell-lines were studied for their cAMP production in response to tropic hormones, 
their mRNA expression of steroidogenic enzymes and its regulation by tropic 
hormones. 
Since steroidogenesis in the adrenal cortex is mediated through a 
cAMP-dependent signaling pathway in response to ACTH stimulation, so it was 
hypothesized that pituitary steroidogenesis could also be mediated through such 
pathway. Of course cAMP production could lead to the expression and release of 
other tropic hormone in the pituitary, such as ACTH (Aguilera et al. 1983), but if 
pituitary cells are capable of steroidogenesis then the event is likely to follow a 
pattern similar to other steroidogenic tissues. Cyclic AMP levels were measured after 
treatments of both cell-lines with CRF and forskolin. Dose-dependent rise of cAMP 
level in response to CRF was observed only at low concentrations of CRF (0.25-0.5 
^M in AtT-20 and 0.125-0.25 |iM in RC-4B/C) (Figure 3.11a and b) which may be 
due to the high potency of CRF in inducing cAMP response in the pituitary. Higher 
concentration of CRF (1 |iM in AtT20, 0.5 |LIM in RC-4B/C), in contrast, resulted in a 
drop of cAMP level which may be due to desensitization of the CRF receptor (Reisine 
and Hoffman 1983). Nonetheless, at an even higher concentration (2 i^M in RC-4B/C), 
CRF was able to augment the cAMP level again in RC-4B/C, possibly because more 
receptors were recruited to transduce the signal. Forskolin is a general stimulator of 
rapid and reversible cAMP production, directly activating the adenylate cyclase 
without interacting with the G protein (Seamon et al 1981). It thus served as a 
positive control for cAMP response in the cell-lines. The rise in cAMP level in 
response to forskolin was greater in RC-4B/C cells increasing 300-fold (Figure 3.12b), 
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and much weaker in AtT-20 cells increasing just 3-fold (Figure 3.12a). This indicates 
that the adenyl cyclase in RC-4B/C cells was fully capable of conveying the 
intra-cellular signal through cAMP, while that in AtT-20 produced a weaker response 
to forskolin than to CRF. 
The expression of P450scc, 3P-HSD, CYP21 and C Y P l l B l steroidogenic 
enzyme mRNA was studied in the two cell-lines. Whilst 3P-HSD was expressed 
consistently in both cell-lines, P450scc was detected only in the RC-4B/C (Figure 
3.13 and 3.14). CYP21 and C Y P l l B l were absent from both cell-lines. Despite using 
the primers that yielded similar sized RT-PCR products from the adrenal and pituitary 
glands of rats and mice, the same primers produced bands with unexpected sizes for 
P450SCC in AtT-20 and C Y P l l B l in RC-4B/C respectively. This suggests the primers 
probably annealed non-specifically to mRNA of some other genes. However, the 
presence of 3p-HSD mRNA in both AtT-20 and RC-4B/C cells, and P450scc mRNA 
in RC-4B/C cells, suggests that both cell lines may be capable of converting 
pregnenolone into progesterone, whereas RC-4B/C cells may convert cholesterol into 
pregnenolone and then progesterone. The absence of CYP21 and C Y P l l B l from 
these cell-lines mRNA does not necessarily preclude the role of these cell types in 
steroidogenesis, for it is known that even with cell lines derived from known 
steroidogenic cells, they may not produce the expected steroids. For example, despite 
having its origins as Leydig cells, mouse Leydig Tumor cells (MLTC-1) produces 
60-fold more progesterone, than the target steroid - testosterone (Panesar et al. 2003). 
This must be due to the repression of enzymes which metabolize progesterone to 
testosterone. 
In Cushing's disease patients, CRF almost instantaneously induced the release of 
Cortisol from the pituitary (Panesar et al, unpublished data). It seems that the release 
of Cortisol is under the regulation of CRF. The effect of CRF on steroidogenic enzyme 
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mRNA expression in the pituitary cell-lines was studied. Since the two cell lines 
responded to CRF by producing cAMP, albeit in a biphasic manner, and since cAMP 
is the propagator of steroidogenic message, which includes the up-regulation of the 
expression of enzymes, it seemed reasonable to test its effect on the expression of the 
two mRNAs. Only the mRNAs of the steroidogenic enzymes expressed in the 
cell-lines were examined, i.e. 3p-HSD in AtT-20, and P450scc and 3P-HSD in 
RC-4B/C. In this experiment, CRF treatments only augmented 3p-HSD mRNA 
expression in AtT-20 cells, while 3P-HSD and P450scc mRNA expressions in 
RC-4B/C were not altered by the treatments (Figure 3.15). The fact that AtT-20 cells 
are corticotrophs and are thus more responsive to CRF, whilst RC-4B/C are composed 
of mixed pituitary cells which are not as responsive. This shows that CRF can act as a 
stimulant of steroidogenic enzyme expression in the pituitary, at least as far as 
3p-HSD is concerned. The reason for the lack of change in steroidogenic enzyme 
expressions in pituitary tissue by the in vivo up- and down-regulation experiments 
aimed at CRF, may be also due to the more heterogeneous environment in live animal 
than in cell-lines. 
The expression of mRNAs for P450scc, 3|3-HSD, CYP21, CYPl lB l and 
1 ip-HSD-1 ill normal rat pituitaries suggests the gland has the potential for the 
synthesis of glucocorticoids, from the cleavage of cholesterol side chain to the 
formation of corticosterone, and its catabolism to 11-dehydrocorticosterone. Could the 
rat pituitary also produce other steroid hormones? With the absence of CYP11B2 
expression in the pituitary, which converts corticosterone to aldosterone, 
mineralocorticoid such as aldosterone, perhaps cannot be produced. Also, CYP 17, 
encoding 17a-hydroxylase, was also absent in the rat pituitary. 17a-hydroxylase 
hydroxylates pregnenolone and progesterone to 170H-pregnenolone and 
170H-progesterone respectively, leading to the formation of sex steroids, such as 
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testosterone and estradiol. This narrows the scope to the production of glucocorticoids 
only by the pituitary. For the mouse pituitary, only 3P-HSD and 11 P-HSD mRNA 
expressions were detected. The discrepancy in the expression patterns between rat and 
mouse may suggest that steroidogenic enzyme mRNA expression in the pituitary is 
species-specific. The absence of P450scc，CYP21 and C Y P l l B l mRNA expression in 
mouse pituitary, which respectively cleave the side-chain of cholesterol; hydroxylate 
steroid precursors such as progesterone or 17a-hydroxyprogesterone to corticosterone 
or Cortisol, suggests mouse pituitary may not be capable of complete de novo 
steroidogenesis. In fact, other studies have often suggested the partial 
steroid-metabolizing ability of the pituitary (Thien et al 1975) (Wiebe et al 1997) 
(Berman et al 1998). 
Although this study has tentatively shown the expression of mRNAs for 
steroidogenic enzymes in normal pituitary gland of rodents, the direct evidence for 
actual steroid hormone production is still lacking. Further studies are therefore 
required. Nonetheless, one may question the reason why pituitary gland may produce 
steroid hormones. A simple answer may just be that they are true to their definition of 
being neurosteroids, but one must bear in mind that the anterior pituitary is of 
non-neural origin. In the intermediate/posterior pituitary, endogenous steroid 
hormones or their derivatives may act as neurotransmitters. 
3a-hydroxy-5-pregnan-20-one (5aP3a), synthesized from progesterone in rat 
intermediate pituitary, was found to potentiate the action of GABA, i.e. chloride ion 
uptake, on melanotrophs in up-regulating the secretion of a-MSH (Berman et al. 
1998); Furthermore, in the rat brain, glucocorticoids and their derivatives reduced the 
action of GABA, while conventional progesterone-derived neurosteroids such as 
allopregnenolone potentiate GABA-ergic actions (Stromberg et al 2005). In the 
presence of steroid-converting enzymes such as 3a-HSD (Thien et al 1975) and 
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5a-reductase (Yokoi et al 1996) in the pituitary, the putative endogenous 
glucocorticoids could well be converted to derivatives that modulate the action of 
GABA on nerve endings in the posterior pituitary for regulating the release of 
vasopressin and oxytocin. 
Alternatively the pituitary steroids act in autocrine/paracrine manner to regulate 
the secretion of pituitary hormones. ACTH synthesis and secretion has been described 
to be regulated in an autocrine/paracrine manner (Schwartz et al. 1998). Briefly, 
ACTH secretion in one corticotroph sub-population is regulated by the other where 
the action is mediated by locally produced factors such as leukemia-inhibiting factor 
(LIF) that up-regulates ACTH secretion. The authors did not identify any negative 
autocrine/paracrine regulatory factor. This role may well be played by the pituitary 
steroids. Since adrenal steroids inhibit ACTH secretion, the pituitary steroids may 
play a role in countering the positive action of LIF. 
In Cushing's disease, the pituitary ACTH secretion is less responsive to the 
negative feedback of Cortisol (Wolfsen and Odell 1980), allowing the corticotrophs to 
secrete ACTH without control. Therefore, the role of pituitary glucocorticoid acting as 
an ultra short-loop inhibitor is unlikely. On the contrary, ultra short-loop activation of 
adrenal steroidogenic enzymes by glucocorticoids has been demonstrated 
(Picard-Hagen et al. 1995), (Feltus et al. 2002). Although this unconventional action 
of glucocorticoids is not yet well explained and incorporated into the traditional 
theory, it may activate pituitary steroidogenesis in an autocrine or paracrine manner. 
In recent decades, attention has been drawn to the interaction between the 
immune system and the endocrine system. Immunomodulators and hormones are 
found to interact in a complex network, in the context of the HPA axis, and at all 
levels along the axis. LIF and its receptor was found to be expressed in both the 
pituitary (Kim and Melmed 1999) and adrenal cortex (Bamberger et al. 2000), 
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enhancing ACTH and glucocorticoid release respectively. In addition, during stress 
and inflammation, a number of cytokines, such as IL-1, IL-6, TNF-a and LIF, are 
expressed and secreted from the adrenal cortex and enhance glucocorticoid release 
(Bornstein et al 2004). A similar relationship may exist between pituitary steroids and 
cytokines. Moreover, the possibility of cytokines regulating the production of 
pituitary steroids cannot be ignored. 
In conclusion, the expressions of mRNAs for steroidogenic enzymes were 
detected in the rat pituitary. These included P450scc, 3P-HSD, CYP21, C Y P l l B l and 
11(3-HSD-1 ill piluitaries of intact animals or P450scc and 3p-HSD in pituitary cell 
lines. Although attempts to up- or down-regulate the expression of these enzymes by 
manipulating the secretion of tropic hormones proved inconclusive in intact animals, 
however, CRF had partial effect on the up-regulation of 3P-HSD particularly in 
AtT-20 cell line. Although by merely showing the expression of steroidogenic enzyme 
mRNA does not confirm the steroidogenic capacity of the pituitary, it certainly 
provides a preliminary evidence for such an event, which may account for the enigma 
of higher Cortisol in the IPS effluent of Cushiiig's disease patients undergoing CRF 
stimulation procedure for lateralization of pituitary microadenomas. 
Future studies 
In order to expand the knowledge about the putative pituitary steroidogenesis, 
further studies can be directed towards examining the relation between this 
phenomenon and other normal and morbid physiological event and to explore the 
involvement of other regulatory factors. 
Directly detecting the release of steroid hormones, including but not limited to 
glucocorticoids, from the pituitary would be the most concrete evidence of pituitary 
steroidogenesis. But with the practical difficulties in performing catheterization in 
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normal human and animals, alternatives must be sought to come up with an equally 
convincing conclusion. The detection of mRNAs for steroidogenic enzymes is one of 
those alternatives, which shows the steroidogenic ability of the pituitary. Detection of 
the steroidogenic enzymes by immunohistochemistry would be the next step in any 
future study of this phenomenon. 
Apart from surgical removal of steroidogenic organs, up-regulation of the HPA 
axis can also be studied by injecting tropic hormones and exerting restraint stress onto 
the animals (Kageyama et al. 2003). Since stress has been shown to alter the amount 
of neurosteroids in the brain, whether this also affects steroidogenesis in the pituitary 
also needs to be studied. Furthermore, the question of pituitary steroid hormones 
playing a role in neuromodulation could be studied. 
Because of time constraint and technical difficulties encountered in setting up a 
Tandem-Mass Spectroscopy method, otherwise this methodology could be used for 
measurement of steroid hormones particularly in the cell lines, without having the 
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Sequence alignment result 
Alignment tool used: 
http:/Avww.di.embnet.om/software/LALIGN form.html 
Gene Pubmed accession number 
of compared sequence 
Rat P450SCC NM_017286.1 
Rat 3P-HSD NM—001007719 
Rat CYP21 RNU56853  
Rat C Y P l l B l RNCP450B 
Rat l lp-HSD NM_017080.1 
Mouse3p-HSD NM_008293  
Mouse 11 (3-HSD NM—008288 
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Appendix 1 
R a t P450SCC 
94.8% identity in 539 nt overlap; score: 2338 E(10，000): 5.4e-187 
10 20 30 40 50 60 
own GGGMGGGCCCACACAGNNANNCCCnTATNCATNCACATNGCCAGNMTTTTNCCAGNA 
NM_017 GAGAACGGCACACACAGAAT---CCATTAT-CAT-CACATG--CAG-AATTT--CCAG-A 
30 40 50 60 70 
70 80 90 100 110 120 
own AGTATGGGCCCCATTTACAGGGNAGMGCTGGGCMCATGGNAGTCAGTTTACATCCTGG 
NM_017 AGTATGG-CCCCATTTACAGGG-AGAAGCTGGGCMCATGG-AGTCAGTmCATCCTGG 
80 90 100 110 120 130 
130 140 150 160 170 180 
own ACCCTMGGACGCAGCGACACTCTTCTCCTGCGAGGGTCCTMCCCGGAGCGCTACCTTG 
NM_017 ACCCTMGGACGCAGCGACTCTCTTCTCCTGCGAGGGTCCTAACCCGGAGCGCTACCTTG 
140 150 160 170 180 190 
190 200 210 220 230 240 
own TGCCCCCCTGGGTGGCCTATCACCAGTATTACCAGAGGCCCATTGGGGTACTGTTTMGA 
NM一〇 17 T(XCCCCCTGOTGGCCTATCACCAGTAmCCAGAGGCCCATTGGGGTACTGTTTAAGA 
200 210 220 230 240 250 
250 260 270 280 290 300 
own GTTCAGATGCCTGGAGGAMGACAGMTTGTCCTAMCCAAGAGGTGATGGCCCCTGACT 
NM_017 GTTCAGATGCCTGGAGGAAAGACAGMTTGTCCTAAACCMGAGGTGATGGCCCCTGACT 
260 270 280 290 300 310 
310 320 330 340 350 360 
own CCATCAAGMCTTCGTGCCCCTGCTGGMGGTGTAGCTCAGGACTTCATCAAAGTCTTAC 
NM_017 CCATCMGMCTTCGTGCCCCTGCTGGAAGGTGTAGCTC/VGGACTTCATCAAAGTOTAC 
320 330 340 350 360 370 
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370 380 390 400 410 420 
own ACAGACGCATCMGCAGCAAAACTCTGGMAGTTCTCAGGGGACATCAGCGATGACCTAT 
NM_017 ACAGACGCATCMGCAGCAMACTCTGGAMGTTCTCAGGGGACATCAGCGATGACCTAT 
380 390 400 410 420 430 
430 440 450 460 470 
own TCCGCnTGCCTTTGAGTCCATCACCAGTGTTGTATTTGGGGAGCGCCTGGGGATGTTG-
NM一017 TCCGCnTGCCTTTGAGTCCATCACCAGTGTTGTATTTGGGGAGCGCCTGGGGATGTTGG 
440 450 460 470 480 490 
480 490 500 510 520 530 
own AGG 脆 TCGTGGACCCTGAGTCCCAGCGGTN-ATCGACGCCGTCTACCAGATGTCCCAC 
NM_017 AGGAGATCGTGGACCCTGAGTCCCAGCGGTTCATCGACGCCGTCTACCAGATGTTCCAC 




95.5% identity in 557 nt overlap; score: 2522 E(10’000): 7.8e-202 
10 20 30 40 50 
own AAATNCNT--CNTTNTGmTGATACTTGCNGCCCTCAAAAATMGGGTNTTCTGMTGT 
NM_001 AAGTCCATTCCnTCTGTOTGATACTTGCGGCCCTCAAMATAAGGGTATTCTGMTGT 
740 750 760 770 780 790 
60 70 80 90 100 110 
own TACTGGCAMTTCTCCATAGCCAATCCAGTGTATGTAGGCMTGTGGCCTGGGCACATAT 
NM_001 TACTGGCAMTTCTCCATAGCCAATCCAGTGTATGTAGGCMTGTGGCCTGGGCACATAT 
800 810 820 830 840 850 
120 130 140 150 160 170 
own TCTGGCTGCCAGGGGCCTTCGAGACCCCMGMGTCACAAMTGTCCMGGACAGTTCTA 
NM_001 TCTGGCTGCCAGGGGCCTTCGAGACCCCMGAAGTCACAAAATGTCCMGGACAGTTCTA 
860 870 880 890 900 910 
180 190 200 210 220 230 
own CTACATCTCAGATGACACCCCTCACCAAAGCTATGATGATmAATTGCACCCTGAGCM 
NM_001 CTACATCTCAGATGACACCCCTCACCAAAGCTATGATGATTTAAATTGCACCCTGAGCM 
920 930 940 950 960 970 
240 250 260 270 280 290 
own GGMTGGGGCCTCCGCCTTGATTCCAGCTGGAGCCTTCCTCTGCCCCTGdmCTGGCT 
NM 一 001 GGAATGGGGCCTCCGCCTTGATrCCAGCTGGAGCCTTCCTCTGCCCCTGCTCTACTGGCT 
980 990 1000 1010 1020 1030 
300 310 320 330 340 350 
own TGCCTTCCTGCTGGAMCTGTGAGCTTCCTGCTGCGTCCATTmCAACTATAGGCCACC 
NM 一 001 TGCCTTCCTGCTGGMACTGTGAGCTTCCTGCTGCGTCCATTmCMCTATAGGCCACC 
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1040 1050 1060 1070 1080 1090 
360 370 380 390 400 410 
own CmTMCTGCCACTTGGTCACACTGTCAAATAGCMGTTCACnTCTCCTACAAGAAAA 
NM—001 CnT-AACTGCCACTTGGTCACACTGTCAAATAGCMGTTCACTTTCTCCTACAAGAM-
1100 1110 1120 1130 1140 1150 
420 430 440 450 460 470 
own GCTCANAGAGATCTGGGCTATGTGCNACnTGTCAGCTGGGGAGGMGCCMGCAGAAM 
NM_001 GCTCAGAGAGATCTGGGCTATGTGCCACTT-GTCAGCTGGG-AGGAAGCCAAGCAGAAAA 
1160 1170 1180 1190 1200 
480 490 500 510 520 530 
own CCTTCGGAGTGGATCGGGACACTNNGTGNAGCAGOCAGGGNGACACTGGNCACM-GTC 
NM_001 CCT-CGGAGTGGATCGGGACACTA-GTGGAGCAGCACAGGGAGACACTGGACACAAAGTC 








(Using NCBI BLAST) 
Score = 299 b i t s ( 1 5 1 ) , Expect = l e -80 
I d e n t i t i e s = 151/151 (100%), Gaps = 0/151 (0%) 
Query 1 CCGCGCCAGAGGCTCGCCCAGGCACACGCGTGCCCCACAGCCAMGGTCGGTATTCTGGG 60 
M M I I I I I I I M M M I I M I I I M I M I I M I I I I M M I I M M I I M M I M I M I 
Sb jc l 1299 CCGCGCCAGAGGCTCGCCCAGGCACACGCGTGCCCCACAGCCAAAGGTCGGTATTCTGGG 1240 
Query 61 ACTCTTGCCGGATTCCAGGAAGCGATCAGGCCAGAACTTGCTGGGCAGTTCCCAAACCAT 120 
I I M I M I M M I I I I M I I I I I M I I M I M I I I M M I M M I i l M M M I I I I I M 
Sbjct 1239 ACTCTTGCCGGATTCCAGGAAGCGATCAGGCCAGMCTTGCTGGGCAGTTCCCMACCAT 1180 
Query 121 CrCAT(XAGGTTGGCGCCTTGGATGTTGGGG 151 
i m m m i i m i m m m m m 




96.4% identity in 279 nt overlap; score: 1310 E(10,000): 8.8e-102 
20 30 40 50 60 70 
own TTNGGTNCNATATGTTNCACTATACCTGGNMGCCAGCCATTTTGTTATTTCCGGAGAGC 
• • • • • ••••••• »_»•••_• • • ******* 
• • • • • • ( • • • • • • _ * * * * * * * * * 
RNCP45 TTCAGTCCMTATGTTCMCTATACCATGGMGCCAGCCATTTTGTTATTTCCGGAGAGC 
30 40 50 60 70 80 
80 90 100 110 120 130 
own GTCTGGGCCTCACAGGCCATGACCTGAAACCTGAGAGCGTGACATTCACTCATGCTCTGC 
RNCP45 GTCTGGGCCTCACAGGCCATGACCTGAAACCTGAGAGCGTGACATTCACTCATGCTCTGC 
90 100 110 120 130 140 
140 150 160 170 180 190 
own ACTCMTGTTCMGTCCACCACACAGCTCATGTTCTTACCCMGAGCTTGACTCGTTGGA 
RNCP45 ACTCAATGTTCMGTCCACCACACAGCTCATGTTCTTACCCMGAGCTTGACTCGTTGGA 
150 160 170 180 190 200 
200 210 220 230 240 250 
own CMGCACCCGGGTGTGGAAAGMCACnTGATTCCTGGGATATCATCTCTGAGTATGTCA 
RNCP45 CMGCACCCGGGTGTGGAMGMCACnTGATTCCTGGGATATCATCTCTGAGTATGTCA 
210 220 230 240 250 260 
260 270 280 290 
own CAAAATGTATCAAGAATGTGTATCGCGAACTGGGCAGAG 
RNCP45 CAAAATGTATCAAGAATGTGTATCGCGAACTGG-CAGAG 
270 280 290 300 
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Rat l ip-HSD-1 
93.7% identity in 446 nt overlap; score: 1917 E(10,000): 1.3e-151 
10 20 30 40 50 
own AAGGGGTACGGNAAAAAA--GGrmTTATGCTAGTMCNCATGGGAGCCCCATGTGGTA 
. . • • 
• • » 參 《 • • • • • • • • • • • • • .. 
• • t • • • • • • • • • • • • • 
NM一017 AMGGGATCGGMGAGAAATGGCATATCAT-CT-GTCMAMTGGGAGCCC-ATGTGGTA 
210 220 230 240 250 260 
60 70 80 90 100 110 
own TTGACTGCAAGGTCGGCNGMGGGCTCCAGNAAGGTGGTGTCTCGCTGCCTTGMCTCGG 
NM一017 TTGACTGCMGGTCGGAGGAAGGGCTCCAG-AAGGTGGTGTCTCGCTGCCTTGMCTCGG 
270 280 290 300 310 320 
120 130 140 150 160 170 
own AGCAGCCTCTGCTCACTATATTGCCGGCACTATGGAAGACATGGCmTGCAGAGCGATT 
NM_017 AGCAGCCTCTGCTCACTACATTGCCGGCACTATGGMGACATGGCmTGCAGAGCGATT 
330 340 350 360 370 380 
180 190 200 210 220 230 
own TGTTGTTGAGGCAGGAAAGCTCTTGGGTGGACTGGACATGCTCATTCTCAATCACATCAC 
NM—〇 17 TGTTGTTGAGGCAGGAAAGCTCTTGGGTGGACTGGACATGCTCATTCTCMTCACATCAC 
390 400 410 420 430 440 
240 250 260 270 280 290 
own ACAGACCACTATGTCTCTCTTCCACGATGATATCCACTCTGTGCGAAGAAGCATGGAGGT 
NM—017 ACAGACCACTATGTCTCTCTTCCACGATGATATCCACTCTGTGCGAAGMGCATGGAGGT 
450 460 470 480 490 500 





510 520 530 540 550 560 
360 370 380 390 400 410 
own TGGCAGCATOCCATCATCTCCTCCATGGCTGGGAM-TGACCCA-CCTCTGATTGGCTC 
NM_017 TGGCAGCATTGCCATCATCTCCTCCATGGCTGGGAAAATGACCCMCCTCTGATTGCTTC 
570 580 590 600 610 620 







94.4% identity in 72 nt overlap; score: 310 E(10’000): 1.7e-18 
10 20 30 40 50 60 
own mCmNNOTAGNMOTAGTAmGCmTAnTCCCCCrTCAAGTCCTAMTCATA 
NM 008 mcnTCAaTAG-MOTAGTArr-GCmTATTTCCCCaTCAAGTCCTAMTCATA 







Mouse l ip -HSD 
94.6% identity in 353 nt overlap; score: 1503 E(10,000): 3.6e-117 
10 20 30 40 50 60 
own AC_CACTOCAGNACCTTCGGCTAGTNCTNCTACTTCCCTAGNACGACATNCCACTCTGT 
» • » » , , • , • • • • t • • • f • • • • • • • • • • • » 
• • • 攀 * • • • » • • • • • * • * • • • • • • • • » » • • 
刚一008 ACATCACT-CAG-ACCT--CGCT-GT-CT-CT-CTTCC--ATGACGACAT-CCACTCTGT 
490 500 510 520 530 
70 80 90 100 110 120 
own GCGMGAGTCATGGNAGGTCMCTTCCTCAGCTACGTGGTCATGAGCACAGCCGCCTTGC 
NM一008 GCGMGAGTCATGG-AGGTCMCTTCCTCAGCTACGTGGTCATGAGCACAGCCGCCTTGC 
540 550 560 570 580 590 
130 140 150 160 170 180 
own CCATGCTGMGCAGAGCAATGGCAGCATTGCCGTCATCTCCTCaTGGCTGGGAAAATGA 
NM一008 CCATGCTGMGCAGAGCMTGGCAGCATTGCCGTCATCTCCTCCTTGGCTGGGAAAATGA 
600 610 620 630 640 650 
190 200 210 220 230 240 
own CCCAGCCTATGATTGCTCCCTACTCTGCMGCMGTTTGCTCTGGATGGGTTCmTCCA 
NM一008 CCCAGCCTATGATTGCTCCCTACTCTGCMGCMGTTTGCTCTGGATGGGTTCmTCCA 
660 670 680 690 700 710 
250 260 270 280 290 300 
own CCAmGMCAGMCTCTACATMCCMGGTCAACGTGTCCATCACTCTCTGTGTCCTTG 
NM—008 CCAmGMCAGMCTCTACATMCCAAGGTCMCGTGTCCATCACTCTCTGTGTCCTTG 
720 730 740 750 760 770 
310 320 330 340 350 
own GCCTCATAGACACAGAMCAGCTATGAAGGAAATCTCTGGGATATTGGACGCC 
NM一008 GCCTCATAGACACAGAAACAGCTATGAAGGAAATCTCTGGGATAATTGACGCC 






































 • • 
- . . . . . . -
 、 ： . ： ， 
. . •

























 . . ? “ 「 
. ：
 .











 . , 、 
. .：
 . . , : •
 . -
 .





 > 。 . 广
 w









 二 ： . 、 「 - , . . . .







 . . ，
 /i
 - V . Y
 -
. . : ； ： ： ：






. . h . : ’ ：
 
藝 





 . . .









































 V . . . - ‘ • 、 . •
 . 
- " v ’ . ： .
. .
 r . r
 .
 . .
 • : .
 .
 , :










 . . .
 .









































 ) ： . 「 . . . •
























C U H K L i b r a r i e s 
圓__1111 
004270310 
